Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptaeal1624

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	AUG 10	Time limit for inactive STN sessions doubles to 40 minutes
NEWS	3	AUG 18	COMPENDEX indexing changed for the Corporate Source (CS) field
NEWS	4	AUG 24	ENCOMPLIT/ENCOMPLIT2 reloaded and enhanced
NEWS	5	AUG 24	CA/CAplus enhanced with legal status information for U.S. patents
NEWS	6	SEP 09	50 Millionth Unique Chemical Substance Recorded in CAS REGISTRY
NEWS	7	SEP 11	WPIDS, WPINDEX, and WPIX now include Japanese FTERM thesaurus
NEWS	8	OCT 21	Derwent World Patents Index Coverage of Indian and Taiwanese Content Expanded
NEWS	9	OCT 21	Derwent World Patents Index enhanced with human translated claims for Chinese Applications and Utility Models
NEWS	10	OCT 27	Free display of legal status information in CA/CAplus, USPATFULL, and USPAT2 in the month of November.
NEWS	11	NOV 23	Addition of SCAN format to selected STN databases
NEWS	12	NOV 23	Annual Reload of IFI Databases

NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:55:17 ON 23 NOV 2009

```
=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.22       0.22

FILE 'REGISTRY' ENTERED AT 12:55:45 ON 23 NOV 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   22 NOV 2009  HIGHEST RN 1193309-59-9
DICTIONARY FILE UPDATES:  22 NOV 2009  HIGHEST RN 1193309-59-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10598262proviso.str
```





```
chain nodes :
12  17  18  20  21  22  23  24  34  35  37  40  41  42  43  44  45  47  48
```

```
ring nodes :
1  2  3  4  5  6  7  8  9  10  25  26  27  28  29  30
ring/chain nodes :
13
chain bonds :
2-12  7-17  7-18  8-20  8-26  9-21  9-22  10-23  10-24  12-13  13-34  13-35  25-44
25-45  27-47  27-48  29-40  29-41  30-42  30-43  34-37
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  5-7  6-10  7-8  8-9  9-10  25-26  25-30  26-27  27-28
 28-29  29-30
exact/norm bonds :
2-12  5-7  6-10  7-8  7-17  7-18  8-9  8-20  8-26  9-10  9-21  9-22  10-23  10-24
12-13  13-34  13-35  25-26  25-30  25-44  25-45  26-27  27-28  27-47  27-48  28-29
29-30  29-40  29-41  30-42  30-43  34-37
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6
isolated ring systems :
containing 25 :


G1:H,N

G2:C,H

G3:C,N

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
12:CLASS  13:CLASS  17:CLASS  18:CLASS  20:CLASS  21:CLASS  22:CLASS  23:CLASS
24:CLASS  25:Atom  26:Atom  27:Atom  28:Atom  29:Atom  30:Atom  34:CLASS  35:CLASS
37:CLASS  40:CLASS  41:CLASS  42:CLASS  43:CLASS  44:CLASS  45:CLASS  47:CLASS
48:CLASS



L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1              STR
```



G1 H,N

G2 C,H

G3 C,N

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1 sss
SAMPLE SEARCH INITIATED 13:01:35 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    39303 TO ITERATE

  5.1% PROCESSED     2000 ITERATIONS                                0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       774207 TO   797913
PROJECTED ANSWERS:               0 TO        0

L2            0 SEA SSS SAM L1

=> s l1 full
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 185.40 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 13:01:41 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   789542 TO ITERATE

 94.9% PROCESSED   749545 ITERATIONS                                2 ANSWERS

100.0% PROCESSED   789542 ITERATIONS                                2 ANSWERS
SEARCH TIME: 00.00.27
```

L3 2 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 190.68 190.90

FILE 'CAPLUS' ENTERED AT 13:02:25 ON 23 NOV 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 23 Nov 2009 VOL 151 ISS 22
FILE LAST UPDATED: 22 Nov 2009 (20091122/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2009

CAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

During November, try the new LSUS format of legal status information in the CA/CAplus family databases for free! Complete details on the number of free displays and other databases participating in this offer appear in NEWS 10.

=> s l3 full
L4 1 L3

=> d ibib abs hitstr
THE ESTIMATED COST FOR THIS REQUEST IS 5.64 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:979643 CAPLUS
DOCUMENT NUMBER: 143:266686
TITLE: Preparation of tetralin derivatives as histamine H3 receptor antagonists
INVENTOR(S): Beavers, Lisa Selsam; Gadski, Robert Alan; Hipskind, Philip Arthur; Jesudason, Cynthia Darshini; Lindsley, Craig William; Lobb, Karen Lynn; Pickard, Richard Todd
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 49 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005082893	A2	20050909	WO 2005-US5491	20050222
WO 2005082893	A3	20060420		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1720861	A2	20061115	EP 2005-723430	20050222
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
US 20070155754	A1	20070705	US 2006-598262	20060823
PRIORITY APPLN. INFO.:			US 2004-547758P P	20040225
			WO 2005-US5491 W	20050222

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): CASREACT 143:266686; MARPAT 143:266686
GI



I



II

AB Tetralins of formula I [R1 = CH2NR3R4, CONR3R4, N-methylpiperazinocarbonyl; R2 = H, NH-alkyl, NR3R4, NH-cycloalkyl, N-methylpiperazino, piperidino, pyrrolidino, etc.; R3 = H, alkyl; R4 = alkyl, phenylalkylene; R3R4 = alkylene, etc.] are prepared which have histamine-H3 receptor antagonist activity. The invention discloses pharmaceutical compns. comprising compds. of formula I as well as methods of using them to treat obesity and other histamine H3 receptor-related diseases. Thus, II was prepared and had Ki value of 1.5 nM against GTP γ[35S].

IT 863925-24-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tetralin derivs. as histamine H3 receptor antagonists)

RN 863925-24-0 CAPLUS

CN 2-Naphthalenecarboxamide, 5,6,7,8-tetrahydro-N-(phenylmethyl)-6-(1-pyrrolidinyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 863925-23-9
CMF C22 H26 N2 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       9.64     200.54

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                      -0.82      -0.82

FILE 'REGISTRY' ENTERED AT 13:07:23 ON 23 NOV 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   22 NOV 2009  HIGHEST RN 1193309-59-9
DICTIONARY FILE UPDATES:  22 NOV 2009  HIGHEST RN 1193309-59-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10598262doublerings.str
```





<12/04/2007> Erich Leese

chain nodes :
12 17 18 20 21 22 23 24 34 35 36 37 38 39 41 42 51 52 53 54
ring nodes :
1 2 3 4 5 6 7 8 9 10 13 25 26 27 28 29 30 44 45 46 47
chain bonds :
2-12 7-17 7-18 8-20 8-26 9-21 9-22 10-23 10-24 12-13 25-38 25-39 27-41
27-42 29-34 29-35 30-36 30-37 44-51 44-52 45-53 45-54
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 13-44 13-47 25-26 25-30
26-27 27-28 28-29 29-30 44-45 45-46 46-47
exact/norm bonds :
2-12 5-7 6-10 7-8 7-17 7-18 8-9 8-20 8-26 9-10 9-21 9-22 10-23 10-24
12-13 13-44 13-47 25-26 25-30 25-38 25-39 26-27 27-28 27-41 27-42 28-29
29-30 29-34 29-35 30-36 30-37 44-45 44-51 44-52 45-46 45-53 45-54 46-47
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 13 : 25 :

G1:H,N

G2:C,H

G3:C,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
12:CLASS 13:Atom 17:CLASS 18:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS
24:CLASS 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom 34:CLASS 35:CLASS
36:CLASS 37:CLASS 38:CLASS 39:CLASS 41:CLASS 42:CLASS 44:CLASS 45:CLASS
46:Atom 47:CLASS 51:CLASS 52:CLASS 53:CLASS 54:CLASS

L5 STRUCTURE UPLOADED

=> d l5
L5 HAS NO ANSWERS
L5 STR



G1 H,N

G2 C,H

G3 C,N

Structure attributes must be viewed using STN Express query preparation.

```
=> s l5 sss
SAMPLE SEARCH INITIATED 13:09:46 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    39287 TO ITERATE

  5.1% PROCESSED     2000 ITERATIONS                                0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       773889 TO   797591
PROJECTED ANSWERS:               0 TO        0

L6            0 SEA SSS SAM L5

=> s l5 full
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 185.40 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 13:09:52 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   789251 TO ITERATE

 94.9% PROCESSED   748945 ITERATIONS                                2 ANSWERS

100.0% PROCESSED   789251 ITERATIONS                                2 ANSWERS
SEARCH TIME: 00.00.30
```

```
L7            2 SEA SSS FUL L5

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   188.28     388.82

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00      -0.82

FILE 'CAPLUS' ENTERED AT 13:11:07 ON 23 NOV 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 23 Nov 2009  VOL 151 ISS 22
FILE LAST UPDATED: 22 Nov 2009  (20091122/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED:  Aug 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE:  Aug 2009

CAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

During November, try the new LSUS format of legal status information
in the CA/CAplus family databases for free!  Complete details on the
number of free displays and other databases participating in this
offer appear in NEWS 10.

=> s l7 full
L8            1 L7

=> d ibib abs hitstr
THE ESTIMATED COST FOR THIS REQUEST IS 5.64 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y
```

L8 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:979643 CAPLUS
DOCUMENT NUMBER: 143:266686
TITLE: Preparation of tetralin derivatives as histamine H3 receptor antagonists
INVENTOR(S): Beavers, Lisa Selsam; Gadski, Robert Alan; Hipskind, Philip Arthur; Jesudason, Cynthia Darshini; Lindsley, Craig William; Lobb, Karen Lynn; Pickard, Richard Todd
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 49 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005082893	A2	20050909	WO 2005-US5491	20050222
WO 2005082893	A3	20060420		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1720861	A2	20061115	EP 2005-723430	20050222
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
US 20070155754	A1	20070705	US 2006-598262	20060823
PRIORITY APPLN. INFO.:			US 2004-547758P P	20040225
			WO 2005-US5491 W	20050222

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): CASREACT 143:266686; MARPAT 143:266686
GI



I



II

AB Tetralins of formula I [R1 = CH2NR3R4, CONR3R4, N-methylpiperazinocarbonyl; R2 = H, NH-alkyl, NR3R4, NH-cycloalkyl, N-methylpiperazino, piperidino, pyrrolidino, etc.; R3 = H, alkyl; R4 = alkyl, phenylalkylene; R3R4 = alkylene, etc.] are prepared which have histamine-H3 receptor antagonist activity. The invention discloses pharmaceutical compns. comprising compds. of formula I as well as methods of using them to treat obesity and other histamine H3 receptor-related diseases. Thus, II was prepared and had Ki value of 1.5 nM against GTP γ[35S].

IT 863925-18-2P 863925-19-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tetralin derivs. as histamine H3 receptor antagonists)

RN 863925-18-2 CAPLUS
CN Methanone, [(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl][5,6,7,8-tetrahydro-6-(1-piperidinyl)-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 863925-19-3 CAPLUS
CN Methanone, [(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl][5,6,7,8-tetrahydro-6-(1-pyrrolidinyl)-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       7.14     395.96

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                      -0.82      -1.64

FILE 'REGISTRY' ENTERED AT 13:12:40 ON 23 NOV 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   22 NOV 2009  HIGHEST RN 1193309-59-9
DICTIONARY FILE UPDATES:  22 NOV 2009  HIGHEST RN 1193309-59-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10598262R2.str
```



chain nodes :
12 17 18 20 21 22 23 32 33 34 35 36 37
ring nodes :
1 2 3 4 5 6 7 8 9 10 13 25 26 27 28
chain bonds :
2-12 7-17 7-18 8-37 8-36 9-20 9-21 10-22 10-23 12-13 25-32 25-33 26-34 26-35
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 13-25 13-28 25-26 26-27 27-28
exact/norm bonds :
2-12 5-7 6-10 7-8 7-17 7-18 8-9 8-37 8-36 9-10 9-20 9-21 10-22 10-23 12-13 13-25 13-28 25-26 25-32 25-33 26-27 26-34 26-35 27-28
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

G1:H,N

G2:C,H

G3:C,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 12:CLASS 13:Atom 17:CLASS 18:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS 25:Atom 26:Atom 27:Atom 28:CLASS 32:CLASS 33:CLASS 34:CLASS 35:CLASS 36:CLASS 37:CLASS

L9 STRUCTURE UPLOADED

=> d l9
L9 HAS NO ANSWERS
L9 STR



G1 H,N

G2 C,H

G3 C,N

Structure attributes must be viewed using STN Express query preparation.

=> s l9 ss
COMBINATION OF STRUCTURE AND TEXT TERMS NOT VALID
The query entered contains both search terms created by
structure-building or screen commands and text search terms. L#s
created via the STRUCTURE or SCREEN commands must be searched in the
structures files separately from text terms or profiles. The L#
answer sets from structure searches can be used in crossover searches
and can be combined with text terms.

=> s l9 sss
SAMPLE SEARCH INITIATED 13:13:21 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 77787 TO ITERATE

2.6% PROCESSED 2000 ITERATIONS 14 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 1539122 TO 1572358
PROJECTED ANSWERS: 9490 TO 12290

L10 14 SEA SSS SAM L9

```
=> s l9 full
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 185.40 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 13:13:28 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -  1558256 TO ITERATE

 95.0% PROCESSED  1480678 ITERATIONS                          9550 ANSWERS

 97.2% PROCESSED  1514971 ITERATIONS                          9552 ANSWERS

100.0% PROCESSED  1558256 ITERATIONS                          9552 ANSWERS
SEARCH TIME: 00.00.41

L11        9552 SEA SSS FUL L9

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   186.84     582.80

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00      -1.64

FILE 'CAPLUS' ENTERED AT 13:14:16 ON 23 NOV 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 23 Nov 2009  VOL 151 ISS 22
FILE LAST UPDATED: 22 Nov 2009  (20091122/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED:  Aug 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE:  Aug 2009

CAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

During November, try the new LSUS format of legal status information
in the CA/CAplus family databases for free!  Complete details on the
```

number of free displays and other databases participating in this offer appear in NEWS 10.

```
=> s l11 full
L12       1809 L11

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       2.00     584.80

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                       0.00      -1.64

FILE 'REGISTRY' ENTERED AT 13:16:48 ON 23 NOV 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   22 NOV 2009  HIGHEST RN 1193309-59-9
DICTIONARY FILE UPDATES:  22 NOV 2009  HIGHEST RN 1193309-59-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10598262nitrogenR2.str
```





chain nodes :
12 17 18 20 21 22 23 32 33 34 35 36 37 38 39
ring nodes :
1 2 3 4 5 6 7 8 9 10 13 25 26 27 28
chain bonds :
2-12 7-17 7-18 8-36 8-37 9-20 9-21 10-22 10-23 12-13 25-32 25-33 26-34
26-35 37-38 37-39
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 13-25 13-28 25-26 26-27
27-28
exact/norm bonds :
2-12 5-7 6-10 7-8 7-17 7-18 8-9 8-36 8-37 9-10 9-20 9-21 10-22 10-23
12-13 13-25 13-28 25-26 25-32 25-33 26-27 26-34 26-35 27-28 37-38 37-39
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

G1:H,N

G2:C,H

G3:C,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
12:CLASS 13:Atom 17:CLASS 18:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS
25:Atom 26:Atom 27:Atom 28:CLASS 32:CLASS 33:CLASS 34:CLASS 35:CLASS
36:CLASS 37:CLASS 38:CLASS 39:CLASS

L13 STRUCTURE UPLOADED

<12/04/2007> Erich Leese

=> d l13
L13 HAS NO ANSWERS
L13 STR



G1 H,N

G2 C,H

G3 C,N

Structure attributes must be viewed using STN Express query preparation.

=> s l3 sss
SAMPLE SEARCH INITIATED 13:17:11 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 39303 TO ITERATE

5.1% PROCESSED 2000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 774207 TO 797913
PROJECTED ANSWERS: 0 TO 0

L14 0 SEA SSS SAM L1

=> s l13 sss
SAMPLE SEARCH INITIATED 13:17:21 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 25958 TO ITERATE

7.7% PROCESSED 2000 ITERATIONS 2 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

```
FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       509516 TO   528804
PROJECTED ANSWERS:             214 TO      824

L15           2 SEA SSS SAM L13

=> s l13 full
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 185.40 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 13:17:59 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   517957 TO ITERATE

100.0% PROCESSED   517957 ITERATIONS                              291 ANSWERS
SEARCH TIME: 00.00.16

L16         291 SEA SSS FUL L13

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     186.84     771.64

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                       0.00      -1.64

FILE 'CAPLUS' ENTERED AT 13:18:36 ON 23 NOV 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 23 Nov 2009  VOL 151 ISS 22
FILE LAST UPDATED: 22 Nov 2009  (20091122/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED:  Aug 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE:  Aug 2009

CAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.
```

During November, try the new LSUS format of legal status information in the CA/CAplus family databases for free! Complete details on the number of free displays and other databases participating in this offer appear in NEWS 10.

```
=> s l16 full
L17         14 L16

=> d ibib abs hitstr tot
THE ESTIMATED COST FOR THIS REQUEST IS 78.96 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y
```

L17 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2009:198266 CAPLUS
DOCUMENT NUMBER: 150:259925
TITLE: Preparation of tetrahydronaphthalenes and chromans as melanin concentrating hormone (MCH) antagonists.
INVENTOR(S): Schwink, Lothar; Stengelin, Siegfried; Gossel, Matthias; Haack, Torsten; Lennig, Petra
PATENT ASSIGNEE(S): Sanofis-Aventis, Fr.
SOURCE: PCT Int. Appl., 162pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009021740	A2	20090219	WO 2008-EP6700	20080814
WO 2009021740	A3	20090514		
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
EP 2025674	A1	20090218	EP 2007-291010	20070815
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				

PRIORITY APPLN. INFO.: EP 2007-291010 A 20070815
OTHER SOURCE(S): MARPAT 150:259925
GI



I

AB Title compds. [I; R1, R2 = H, alkyl, alkoxyalkyl, alkenyl, alkynyl, acyl; NR1R2 = (substituted) 4-10 membered mono-, bi-, or spirocyclyl; R3, R4, R5 = H, F, Cl, Br, iodo, OH, CF3, NO2, cyano, OCF3, alkoxy, alkylthio, etc.; R6, R61, R7, R71 = H, F, alkyl, OH, alkoxy; R8 = H, alkyl; L1 = cycloalkylene, (alkyl-substituted) CH2, CH2CH2; L2 = bond, (alkyl-substituted) CH2; L3 = bond, linker with 1-4 members selected from

O, S, SO2, C.tplbond.C, CO, imino, (alkyl-substituted) CH2, etc.; A = 5-6 membered (substituted) (hetero)arylene; B = alkyl, alkoxyalkyl, hydroxyalkyl, 3-10 membered mono-, bi-, or spirocyclic nonarom. (heterocyclic) (substituted) ring; X = O, (substituted) CH2], were prepared Thus, 4-[(S)-1-(tetrahydrofuran-2-yl)methoxy]benzoic acid (preparation given) in N-methylpyrrolidone was treated with HATU, Et3N, and (S)-6-pyrrolidin-1-ylmethyl-1,2,3,4-tetrahydronaphthalen-2-ylamine (preparation given) in N-methylpyrrolidone followed by stirring for 12 h to give N-[(S)-6-pyrrolidin-1-ylmethyl-1,2,3,4-tetrahydronaphthalen-2-yl]-4-[(S)-1-(tetrahydrofuran-2-yl)methoxy]benzamide. The latter showed an IC50 of 0.09 μM in a calcium mobilization assay.

IT 1119016-66-8P 1119016-68-0P 1119018-13-1P
1119018-20-0P 1119018-22-2P 1119018-24-4P
1119018-28-8P 1119018-30-2P 1119018-34-6P
1119018-43-7P 1119018-49-3P 1119018-53-9P
1119018-59-5P 1119018-71-1P 1119018-90-4P
1119019-05-4P 1119019-07-6P 1119019-13-4P
1119019-15-6P 1119019-19-0P 1119019-21-4P
1119019-23-6P 1119019-25-8P 1119019-41-8P
1119019-45-2P 1119019-47-4P 1119019-67-8P
1119019-83-8P 1119019-89-4P 1119256-53-9P
1119256-54-0P 1119256-56-2P 1119256-57-3P
1119256-60-8P 1119256-61-9P 1119256-62-0P
1119256-63-1P 1119256-64-2P 1119256-65-3P
1119256-66-4P 1119256-69-7P 1119256-70-0P
1119256-71-1P 1119256-73-3P 1119257-12-3P
1119257-58-7P 1119257-64-5P 1119257-73-6P
1119257-74-7P 1119257-75-8P 1119257-76-9P
1119257-77-0P 1119257-78-1P 1119257-79-2P
1119257-81-6P 1119257-84-9P 1119257-91-8P
1119257-93-0P 1119257-96-3P 1119257-97-4P
1119257-99-6P 1119258-01-3P 1119258-02-4P
1119258-03-5P 1119258-06-8P 1119258-10-4P
1119258-14-8P 1119258-27-3P 1119258-33-1P
1119258-35-3P 1119258-37-5P 1119258-41-1P
1119258-43-3P 1119258-47-7P 1119258-55-7P
1119258-57-9P 1119258-59-1P 1119258-69-3P
1119258-71-7P 1119258-74-0P 1119258-76-2P
1119259-46-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tetrahydronaphthalenes and chromans as MCH antagonists)

RN 1119016-66-8 CAPLUS
CN Benzamide, 4-[[(2S)-tetrahydro-2-furanyl]methoxy]-N-[(2S)-1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119016-68-0 CAPLUS
CN Benzamide, 4-[[(2S)-tetrahydro-2-furanyl]methoxy]-N-[(2S)-1,2,3,4-tetrahydro-6-[1-(1-pyrrolidinyl)ethyl]-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119018-13-1 CAPLUS
CN Benzamide, 4-[[(2S)-tetrahydro-2-furanyl]methoxy]-N-[(2S)-1,2,3,4-tetrahydro-6-[(4-methyl-1-piperazinyl)methyl]-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119018-20-0 CAPLUS
CN Benzamide, 4-[[(2S)-tetrahydro-2-furanyl]methoxy]-N-[(2S)-1,2,3,4-tetrahydro-6-[(4-hydroxy-1-piperidinyl)methyl]-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119018-22-2 CAPLUS
CN Benzamide, 4-[[(2S)-tetrahydro-2-furanyl]methoxy]-N-[(2S)-1,2,3,4-tetrahydro-6-[(3-hydroxy-1-piperidinyl)methyl]-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119018-24-4 CAPLUS
CN Benzamide, 4-[[(2S)-tetrahydro-2-furanyl]methoxy]-N-[(2S)-1,2,3,4-tetrahydro-6-[[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]methyl]-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119018-28-8 CAPLUS
CN Benzamide, N-[(2S)-6-[(4-acetyl-1-piperazinyl)methyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-4-[[(2S)-tetrahydro-2-furanyl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119018-30-2 CAPLUS
CN Benzamide, 4-[[(2S)-tetrahydro-2-furanyl]methoxy]-N-[(2S)-1,2,3,4-tetrahydro-6-[(4-methyl-1-piperidinyl)methyl]-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119018-34-6 CAPLUS
CN Benzamide, N-[(2S)-6-[(3,4-dihydro-2(1H)-isoquinolinyl)methyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-4-[[(2S)-tetrahydro-2-furanyl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119018-43-7 CAPLUS
CN Benzamide, N-[(2S)-6-[(2-ethyl-1-piperidinyl)methyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-4-[[(2S)-tetrahydro-2-furanyl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119018-49-3 CAPLUS
CN Benzamide, N-[(2S)-6-[[3-(acetylamino)-1-pyrrolidinyl]methyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-4-[[(2S)-tetrahydro-2-furanyl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119018-53-9 CAPLUS
CN Benzamide, 4-[[(2S)-tetrahydro-2-furanyl]methoxy]-N-[(2S)-1,2,3,4-tetrahydro-6-[[(3S)-3-hydroxy-1-pyrrolidinyl]methyl]-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119018-59-5 CAPLUS
CN Benzamide, 4-[[(2S)-tetrahydro-2-furanyl]methoxy]-N-[(2S)-1,2,3,4-tetrahydro-6-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]methyl]-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119018-71-1 CAPLUS
CN Benzamide, 4-[[(2S)-tetrahydro-2-furanyl]methoxy]-N-[(2S)-1,2,3,4-tetrahydro-6-[[(3R)-3-hydroxy-1-pyrrolidinyl]methyl]-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119018-90-4 CAPLUS
CN Benzamide, 4-[[(2S)-tetrahydro-2-furanyl]methoxy]-N-[(2S)-1,2,3,4-tetrahydro-6-[(3-oxo-1-piperazinyl)methyl]-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119019-05-4 CAPLUS
CN Benzamide, 4-[[(2S)-tetrahydro-2-furanyl]methoxy]-N-[(2S)-1,2,3,4-tetrahydro-6-[[2-(methoxymethyl)-1-piperidinyl]methyl]-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119019-07-6 CAPLUS
CN Benzamide, 4-[[(2S)-tetrahydro-2-furanyl]methoxy]-N-[(2S)-1,2,3,4-tetrahydro-6-[(4-methoxy-1-piperidinyl)methyl]-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119019-13-4 CAPLUS
CN Benzamide, N-[(2S)-6-[(1R,4S)-2-azabicyclo[2.2.1]hept-2-ylmethyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-4-[[(2S)-tetrahydro-2-furanyl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119019-15-6 CAPLUS
CN Benzamide, N-[(2S)-6-[(4-cyano-1-piperidinyl)methyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-4-[[(2S)-tetrahydro-2-furanyl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119019-19-0 CAPLUS
CN Benzamide, N-[(2S)-6-[[(3R)-3-fluoro-1-pyrrolidinyl]methyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-4-[[(2S)-tetrahydro-2-furanyl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119019-21-4 CAPLUS
CN Benzamide, 4-[[(2S)-tetrahydro-2-furanyl]methoxy]-N-[(2S)-1,2,3,4-tetrahydro-6-[(3-methoxy-1-piperidinyl)methyl]-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119019-23-6 CAPLUS
CN Benzamide, 4-[[(2S)-tetrahydro-2-furanyl]methoxy]-N-[(2S)-1,2,3,4-tetrahydro-6-[[4-(1-hydroxy-1-methylethyl)-1-piperidinyl]methyl]-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119019-25-8 CAPLUS
CN Benzamide, N-[(2S)-6-[(3-fluoro-1-piperidinyl)methyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-4-[[(2S)-tetrahydro-2-furanyl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119019-41-8 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[[(6S)-5,6,7,8-tetrahydro-6-[[4-[[(2S)-tetrahydro-2-furanyl]methoxy]benzoyl]amino]-2-naphthalenyl]methyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 1119019-45-2 CAPLUS
CN Benzamide, 4-[[(2S)-tetrahydro-2-furanyl]methoxy]-N-[(2S)-1,2,3,4-tetrahydro-6-[(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-ylmethyl]-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119019-47-4 CAPLUS
CN Benzamide, 4-[[(2S)-tetrahydro-2-furanyl]methoxy]-N-[(2S)-1,2,3,4-tetrahydro-6-[[3-(methylsulfonyl)-1-pyrrolidinyl]methyl]-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119019-67-8 CAPLUS
CN Benzamide, N-[(2S)-6-(1,4-dioxa-8-azaspiro[4.5]dec-8-ylmethyl)-1,2,3,4-tetrahydro-2-naphthalenyl]-4-[[(2S)-tetrahydro-2-furanyl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119019-83-8 CAPLUS
CN Benzamide, 4-[[(2S)-tetrahydro-2-furanyl]methoxy]-N-[(2S)-1,2,3,4-tetrahydro-6-[(3-methoxy-1-pyrrolidinyl)methyl]-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119019-89-4 CAPLUS
CN Benzamide, N-[(2S)-6-[(5,6-dihydro-1,2,4-triazolo[4,3-a]pyrazin-7(8H)-yl)methyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-4-[[(2S)-tetrahydro-2-furanyl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119256-53-9 CAPLUS
CN Benzamide, N-methyl-4-[[(2S)-tetrahydro-2-furanyl]methoxy]-N-[(2S)-1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119256-54-0 CAPLUS
CN Benzamide, 4-[[(2S)-tetrahydro-2-furanyl]methoxy]-N-[(2R)-1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119256-56-2 CAPLUS
CN Benzamide, 4-[[(2S)-tetrahydro-2-furanyl]methoxy]-N-[(2S)-1,2,3,4-tetrahydro-6-[(2-methyl-1-pyrrolidinyl)methyl]-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119256-57-3 CAPLUS
CN Benzamide, 4-[[(2S)-tetrahydro-2-furanyl]methoxy]-N-[(2S)-1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119256-60-8 CAPLUS
CN Benzamide, N-[(2S)-6-[(2,5-dimethyl-1-pyrrolidinyl)methyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-4-[[(2S)-tetrahydro-2-furanyl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119256-61-9 CAPLUS
CN Benzamide, N-[(2S)-6-[(4-fluoro-1-piperidinyl)methyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-4-[[(2S)-tetrahydro-2-furanyl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119256-62-0 CAPLUS
CN Benzamide, N-[(2S)-6-[(4,4-difluoro-1-piperidinyl)methyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-4-[[(2S)-tetrahydro-2-furanyl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119256-63-1 CAPLUS
CN Benzamide, N-[(2S)-6-[[(3S)-3-fluoro-1-pyrrolidinyl]methyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-4-[[(2S)-tetrahydro-2-furanyl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119256-64-2 CAPLUS
CN Benzamide, N-[(2S)-6-(7-azabicyclo[2.2.1]hept-7-ylmethyl)-1,2,3,4-tetrahydro-2-naphthalenyl]-4-[[(2S)-tetrahydro-2-furanyl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119256-65-3 CAPLUS
CN Benzamide, 4-[[(2S)-tetrahydro-2-furanyl]methoxy]-N-[(2S)-1,2,3,4-tetrahydro-6-[[(4aR,8aS)-octahydro-1(2H)-quinolinyl]methyl]-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119256-66-4 CAPLUS
CN Benzamide, N-[(2S)-6-[(hexahydrocyclopenta[c]pyrrol-2(1H)-yl)methyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-4-[[(2S)-tetrahydro-2-furanyl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119256-69-7 CAPLUS
CN Benzamide, 4-[[(2S)-tetrahydro-2-furanyl]methoxy]-N-[(2S)-1,2,3,4-tetrahydro-6-[2-(1-pyrrolidinyl)ethyl]-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119256-70-0 CAPLUS
CN Benzamide, 4-[[(2S)-tetrahydro-2-furanyl]methoxy]-N-[(2S)-1,2,3,4-tetrahydro-6-[2-(4-hydroxy-4-methyl-1-piperidinyl)ethyl]-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119256-71-1 CAPLUS
CN Benzamide, 4-[[(2S)-tetrahydro-2-furanyl]methoxy]-N-[(2S)-1,2,3,4-tetrahydro-6-[2-(4-methoxy-1-piperidinyl)ethyl]-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119256-73-3 CAPLUS
CN Benzamide, 4-[[(2S)-tetrahydro-2-furanyl]methoxy]-N-[(2S)-1,2,3,4-tetrahydro-6-[[(2R)-2-(methoxymethyl)-1-pyrrolidinyl]methyl]-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119257-12-3 CAPLUS
CN Benzamide, N-[(2S)-6-[(1S,4R)-2-azabicyclo[2.2.1]hept-2-ylmethyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-4-[[(2S)-tetrahydro-2-furanyl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119257-58-7 CAPLUS
CN Benzamide, 4-[[(2S)-tetrahydro-2-furanyl]methoxy]-N-[(2S)-1,2,3,4-tetrahydro-6-[2-(4-methyl-1-piperidinyl)ethyl]-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119257-64-5 CAPLUS
CN Benzamide, 4-[[(2S)-tetrahydro-2-furanyl]methoxy]-N-[(2S)-1,2,3,4-tetrahydro-6-[2-(4-hydroxy-1-piperidinyl)ethyl]-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119257-73-6 CAPLUS
CN Benzamide, N-[(2S)-6-[(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-ylmethyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-4-[[(2S)-tetrahydro-2-furanyl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119257-74-7 CAPLUS
CN Benzamide, 4-[[(2S)-tetrahydro-2-furanyl]methoxy]-N-[(2S)-1,2,3,4-tetrahydro-6-[[(3-endo)-3-hydroxy-8-azabicyclo[3.2.1]oct-8-yl]methyl]-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119257-75-8 CAPLUS
CN Benzamide, N-[(2S)-6-(3-azabicyclo[3.2.1]oct-3-ylmethyl)-1,2,3,4-tetrahydro-2-naphthalenyl]-4-[[(2S)-tetrahydro-2-furanyl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119257-76-9 CAPLUS
CN Benzamide, N-[(2S)-6-[[(1S,4S)-5-acetyl-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-4-[[(2S)-tetrahydro-2-furanyl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119257-77-0 CAPLUS
CN Benzamide, N-[(2S)-6-(2-azabicyclo[2.2.2]oct-2-ylmethyl)-1,2,3,4-tetrahydro-2-naphthalenyl]-4-[[(2S)-tetrahydro-2-furanyl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119257-78-1 CAPLUS
CN Benzamide, N-[(2S)-6-[2-(1S,4R)-2-azabicyclo[2.2.1]hept-2-ylethyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-4-[[(2S)-tetrahydro-2-furanyl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119257-79-2 CAPLUS
CN Benzamide, N-[(2S)-6-[2-(2-azabicyclo[2.2.2]oct-2-yl)ethyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-4-[[(2S)-tetrahydro-2-furanyl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119257-81-6 CAPLUS

CN Benzamide, N-[(2S)-6-[2-(3-azabicyclo[3.2.1]oct-3-yl)ethyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-4-[[(2S)-tetrahydro-2-furanyl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119257-84-9 CAPLUS
CN Benzamide, N-[(2S)-6-(8-azabicyclo[3.2.1]oct-8-ylmethyl)-1,2,3,4-tetrahydro-2-naphthalenyl]-4-[[(2S)-tetrahydro-2-furanyl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119257-91-8 CAPLUS
CN Benzamide, N-[(2S)-6-[(3,3-dimethyl-1-piperidinyl)methyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-4-[[(2S)-tetrahydro-2-furanyl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119257-93-0 CAPLUS
CN Benzamide, N-[(2S)-6-[(4,4-dimethyl-1-piperidinyl)methyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-4-[[(2S)-tetrahydro-2-furanyl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119257-96-3 CAPLUS
CN Benzamide, 4-[[(2S)-tetrahydro-2-furanyl]methoxy]-N-[(2S)-1,2,3,4-tetrahydro-6-[[4-(methoxymethyl)-1-piperidinyl]methyl]-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119257-97-4 CAPLUS
CN Benzamide, N-[(2S)-6-[(2-ethyl-1-pyrrolidinyl)methyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-4-[[(2S)-tetrahydro-2-furanyl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119257-99-6 CAPLUS
CN Benzamide, 4-[[(2S)-tetrahydro-2-furanyl]methoxy]-N-[(2S)-1,2,3,4-tetrahydro-6-[[(2R)-2-methyl-1-piperidinyl]methyl]-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119258-01-3 CAPLUS
CN Benzamide, N-[(2S)-6-[(3,5-dimethyl-1-piperidinyl)methyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-4-[[(2S)-tetrahydro-2-furanyl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119258-02-4 CAPLUS
CN Benzamide, 4-[[(2S)-tetrahydro-2-furanyl]methoxy]-N-[(2S)-1,2,3,4-tetrahydro-6-[[2-(2-methylpropyl)-1-pyrrolidinyl]methyl]-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119258-03-5 CAPLUS
CN Benzamide, 4-[[(2S)-tetrahydro-2-furanyl]methoxy]-N-[(2S)-1,2,3,4-tetrahydro-6-[[2-(1-methylethyl)-1-piperidinyl]methyl]-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119258-06-8 CAPLUS
CN Benzamide, N-[(2S)-6-[[2-(1,1-dimethylethyl)-1-pyrrolidinyl]methyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-4-[[(2S)-tetrahydro-2-furanyl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119258-10-4 CAPLUS
CN Benzamide, N-[(2S)-6-(2-azaspiro[4.5]dec-2-ylmethyl)-1,2,3,4-tetrahydro-2-naphthalenyl]-4-[[(2S)-tetrahydro-2-furanyl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119258-14-8 CAPLUS
CN Benzamide, N-[(2S)-6-(6-azaspiro[2.5]oct-6-ylmethyl)-1,2,3,4-tetrahydro-2-naphthalenyl]-4-[[(2S)-tetrahydro-2-furanyl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119258-27-3 CAPLUS
CN Benzamide, N-[(2S)-6-[[4-(1,1-dimethylethyl)-1-piperidinyl]methyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-4-[[(2S)-tetrahydro-2-furanyl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119258-33-1 CAPLUS
CN Benzamide, 4-[[(2S)-tetrahydro-2-furanyl]methoxy]-N-[(2S)-1,2,3,4-tetrahydro-6-[(4-propyl-1-piperidinyl)methyl]-2-naphthalenyl]- (CA INDEX

NAME)

Absolute stereochemistry.



RN 1119258-35-3 CAPLUS
CN Benzamide, N-[(2S)-6-[(4-ethoxy-1-piperidinyl)methyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-4-[[(2S)-tetrahydro-2-furanyl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119258-37-5 CAPLUS
CN Benzamide, N-[(2S)-6-(2-azaspiro[4.4]non-2-ylmethyl)-1,2,3,4-tetrahydro-2-naphthalenyl]-4-[[(2S)-tetrahydro-2-furanyl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119258-41-1 CAPLUS
CN 2-Pyridinecarboxamide, 5-[[(2S)-tetrahydro-2-furanyl]methoxy]-N-[(2S)-1,2,3,4-tetrahydro-6-[(4-methyl-1-piperidinyl)methyl]-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119258-43-3 CAPLUS
CN 2-Pyridinecarboxamide, N-[(2S)-6-[(4,4-dimethyl-1-piperidinyl)methyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-5-[[(2S)-tetrahydro-2-furanyl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119258-47-7 CAPLUS
CN 2-Pyridinecarboxamide, N-[(2S)-6-(2-azaspiro[4.4]non-2-ylmethyl)-1,2,3,4-tetrahydro-2-naphthalenyl]-5-[[(2S)-tetrahydro-2-furanyl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119258-55-7 CAPLUS
CN 2-Pyridinecarboxamide, N-[(2S)-6-[(hexahydrocyclopenta[c]pyrrol-2(1H)-yl)methyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-5-[[(2S)-tetrahydro-2-furanyl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119258-57-9 CAPLUS
CN 2-Pyridinecarboxamide, 5-[[(2S)-tetrahydro-2-furanyl]methoxy]-N-[(2S)-1,2,3,4-tetrahydro-6-[(4-methoxy-1-piperidinyl)methyl]-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119258-59-1 CAPLUS
CN 2-Pyridinecarboxamide, N-[(2S)-6-[(4-ethoxy-1-piperidinyl)methyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-5-[[(2S)-tetrahydro-2-furanyl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119258-69-3 CAPLUS
CN 2-Pyridinecarboxamide, N-[(2S)-6-[(1S,4R)-2-azabicyclo[2.2.1]hept-2-ylmethyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-5-[[(2S)-tetrahydro-2-furanyl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119258-71-7 CAPLUS
CN 2-Pyridinecarboxamide, N-[(2S)-6-(2-azabicyclo[2.2.2]oct-2-ylmethyl)-1,2,3,4-tetrahydro-2-naphthalenyl]-5-[[(2S)-tetrahydro-2-furanyl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119258-74-0 CAPLUS
CN 2-Pyridinecarboxamide, 5-[[(2S)-tetrahydro-2-furanyl]methoxy]-N-[(2S)-1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119258-76-2 CAPLUS
CN 2-Pyridinecarboxamide, 5-[[(2S)-tetrahydro-2-furanyl]methoxy]-N-[(2S)-1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119259-46-9 CAPLUS
CN Benzamide, 4-[[(2S)-tetrahydro-2-furanyl]methoxy]-N-[(2S)-1,2,3,4-tetrahydro-6-[(1R)-1-(4-methyl-1-piperidinyl)ethyl]-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 1119020-01-7P 1119020-11-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of tetrahydronaphthalenes and chromans as MCH antagonists)
RN 1119020-01-7 CAPLUS
CN Carbamic acid, N-[(2S)-1,2,3,4-tetrahydro-6-(1-pyrrolidinylcarbonyl)-2-naphthalenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 1119020-11-9 CAPLUS
CN 2-Naphthalenamine, 1,2,3,4-tetrahydro-N-methyl-6-(1-pyrrolidinylmethyl)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L17 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2009:191503 CAPLUS
DOCUMENT NUMBER: 150:259959
TITLE: Preparation of tetrahydronaphthalenes as antidiabetic agents
INVENTOR(S): Schwink, Lothar; Stengelin, Siegfried; Gossel, Matthias; Haack, Torsten; Lennig, Petra
PATENT ASSIGNEE(S): Sanofi-Aventis, Fr.
SOURCE: Eur. Pat. Appl., 55pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 2025674	A1	20090218	EP 2007-291010	20070815
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
WO 2009021740	A2	20090219	WO 2008-EP6700	20080814
WO 2009021740	A3	20090514		
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				

PRIORITY APPLN. INFO.: EP 2007-291010 A 20070815
GI



I



II



III



IV

AB Title compds. I [Z = L1-NR1R2; Y = L2-A-L3-B; R1, R2 = H, alkyl, alkenyl, etc.; L1 = cycloalkyl with provisos; R3, R4, R5 = H, halo, OH, etc.; X = O, CR43R43'; R6, R6', R7, R7', R43, R43' = H, F, alkyl, etc.; R8 = H, alkyl; L2 = bond, CR44R45; R44, R45 = H, alkyl; A = 5 or 6-membered aromatic ring with provisos; L3 = bond, O, S, SO2, etc.; B = alkyl, alkoxyalkyl, hydroxyalkyl, etc.] and their pharmaceutically acceptable salts and formulations were prepared For example, HATU-mediated coupling of amine II and benzoic acid III afforded tetrahydronaphthalene IV. In melanin-concentrating hormone receptor calcium influx assays, 2 examples of compds. I exhibited IC50 values of 0.13 and 0.67 μM.

IT 1119016-70-4P 1119016-75-9P 1119016-77-1P
1119016-79-3P 1119016-81-7P 1119016-83-9P
1119016-85-1P 1119016-87-3P 1119016-89-5P
1119016-91-9P 1119016-93-1P 1119016-95-3P
1119016-97-5P 1119016-99-7P 1119017-85-4P
1119018-13-1P 1119018-20-0P 1119018-22-2P
1119018-24-4P 1119018-28-8P 1119018-30-2P
1119018-34-6P 1119018-43-7P 1119018-49-3P
1119018-53-9P 1119018-59-5P 1119018-71-1P
1119018-82-4P 1119018-90-4P 1119019-05-4P
1119019-07-6P 1119019-13-4P 1119019-15-6P
1119019-19-0P 1119019-21-4P 1119019-23-6P
1119019-25-8P 1119019-41-8P 1119019-45-2P
1119019-47-4P 1119019-67-8P 1119019-71-4P
1119019-83-8P 1119019-89-4P
RL: PAC (Pharmacological activity); PRPH (Prophetic); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tetrahydronaphthalenes as antidiabetic agents)

RN 1119016-70-4 CAPLUS
CN Benzamide, 4-[[(2S)-tetrahydro-2-furanyl]methoxy]-N-[(2S)-1,2,3,4-tetrahydro-6-[1-methyl-1-(1-pyrrolidinyl)ethyl]-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119016-75-9 CAPLUS
CN Benzamide, 4-[[(2S)-tetrahydro-2-furanyl]methoxy]-N-[(2S)-1,2,3,4-tetrahydro-5-methyl-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119016-77-1 CAPLUS
CN Benzamide, 4-[[(2S)-tetrahydro-2-furanyl]methoxy]-N-[(2S)-1,2,3,4-tetrahydro-7-methyl-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119016-79-3 CAPLUS
CN Benzamide, 2-fluoro-4-[[(2S)-tetrahydro-2-furanyl]methoxy]-N-[(2S)-1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119016-81-7 CAPLUS
CN Benzamide, 3-fluoro-4-[[(2S)-tetrahydro-2-furanyl]methoxy]-N-[(2S)-1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119016-83-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1119016-85-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1119016-87-3 CAPLUS
CN Benzamide, 4-(2-oxetanylmethoxy)-N-[(2S)-1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119016-89-5 CAPLUS
CN Benzamide, 4-[(1-hydroxycyclobutyl)methoxy]-N-[(2S)-1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119016-91-9 CAPLUS
CN Benzamide, 4-[(tetrahydro-2H-pyran-2-yl)methoxy]-N-[(2S)-1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119016-93-1 CAPLUS
CN Benzamide, 4-[(tetrahydro-2H-pyran-4-yl)methoxy]-N-[(2S)-1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119016-95-3 CAPLUS
CN Benzamide, 4-[(tetrahydro-3-furanyl)methoxy]-N-[(2S)-1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119016-97-5 CAPLUS
CN Benzamide, 4-(1,3-dioxolan-4-ylmethoxy)-N-[(2S)-1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119016-99-7 CAPLUS
CN Benzamide, 4-(1,3-dioxolan-2-ylmethoxy)-N-[(2S)-1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119017-85-4 CAPLUS
CN Benzamide, 4-[[(2S)-tetrahydro-2-furanyl]methoxy]-N-[(2S)-1,2,3,4-tetrahydro-6-[[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]methyl]-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119018-13-1 CAPLUS
CN Benzamide, 4-[[(2S)-tetrahydro-2-furanyl]methoxy]-N-[(2S)-1,2,3,4-tetrahydro-6-[(4-methyl-1-piperazinyl)methyl]-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119018-20-0 CAPLUS
CN Benzamide, 4-[[(2S)-tetrahydro-2-furanyl]methoxy]-N-[(2S)-1,2,3,4-tetrahydro-6-[(4-hydroxy-1-piperidinyl)methyl]-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119018-22-2 CAPLUS
CN Benzamide, 4-[[(2S)-tetrahydro-2-furanyl]methoxy]-N-[(2S)-1,2,3,4-tetrahydro-6-[(3-hydroxy-1-piperidinyl)methyl]-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119018-24-4 CAPLUS
CN Benzamide, 4-[[(2S)-tetrahydro-2-furanyl]methoxy]-N-[(2S)-1,2,3,4-tetrahydro-6-[[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]methyl]-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119018-28-8 CAPLUS
CN Benzamide, N-[(2S)-6-[(4-acetyl-1-piperazinyl)methyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-4-[[(2S)-tetrahydro-2-furanyl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119018-30-2 CAPLUS
CN Benzamide, 4-[[(2S)-tetrahydro-2-furanyl]methoxy]-N-[(2S)-1,2,3,4-tetrahydro-6-[(4-methyl-1-piperidinyl)methyl]-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119018-34-6 CAPLUS
CN Benzamide, N-[(2S)-6-[(3,4-dihydro-2(1H)-isoquinolinyl)methyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-4-[[(2S)-tetrahydro-2-furanyl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119018-43-7 CAPLUS
CN Benzamide, N-[(2S)-6-[(2-ethyl-1-piperidinyl)methyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-4-[[(2S)-tetrahydro-2-furanyl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119018-49-3 CAPLUS
CN Benzamide, N-[(2S)-6-[[3-(acetylamino)-1-pyrrolidinyl]methyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-4-[[(2S)-tetrahydro-2-furanyl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119018-53-9 CAPLUS
CN Benzamide, 4-[[(2S)-tetrahydro-2-furanyl]methoxy]-N-[(2S)-1,2,3,4-tetrahydro-6-[[(3S)-3-hydroxy-1-pyrrolidinyl]methyl]-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119018-59-5 CAPLUS
CN Benzamide, 4-[[(2S)-tetrahydro-2-furanyl]methoxy]-N-[(2S)-1,2,3,4-tetrahydro-6-[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]methyl]-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119018-71-1 CAPLUS
CN Benzamide, 4-[[(2S)-tetrahydro-2-furanyl]methoxy]-N-[(2S)-1,2,3,4-tetrahydro-6-[[(3R)-3-hydroxy-1-pyrrolidinyl]methyl]-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119018-82-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1119018-90-4 CAPLUS
CN Benzamide, 4-[[(2S)-tetrahydro-2-furanyl]methoxy]-N-[(2S)-1,2,3,4-tetrahydro-6-[(3-oxo-1-piperazinyl)methyl]-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119019-05-4 CAPLUS
CN Benzamide, 4-[[(2S)-tetrahydro-2-furanyl]methoxy]-N-[(2S)-1,2,3,4-tetrahydro-6-[[2-(methoxymethyl)-1-piperidinyl]methyl]-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119019-07-6 CAPLUS
CN Benzamide, 4-[[(2S)-tetrahydro-2-furanyl]methoxy]-N-[(2S)-1,2,3,4-tetrahydro-6-[(4-methoxy-1-piperidinyl)methyl]-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119019-13-4 CAPLUS
CN Benzamide, N-[(2S)-6-[(1R,4S)-2-azabicyclo[2.2.1]hept-2-ylmethyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-4-[[(2S)-tetrahydro-2-furanyl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119019-15-6 CAPLUS
CN Benzamide, N-[(2S)-6-[(4-cyano-1-piperidinyl)methyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-4-[[(2S)-tetrahydro-2-furanyl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119019-19-0 CAPLUS
CN Benzamide, N-[(2S)-6-[[(3R)-3-fluoro-1-pyrrolidinyl]methyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-4-[[(2S)-tetrahydro-2-furanyl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119019-21-4 CAPLUS
CN Benzamide, 4-[[(2S)-tetrahydro-2-furanyl]methoxy]-N-[(2S)-1,2,3,4-tetrahydro-6-[(3-methoxy-1-piperidinyl)methyl]-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119019-23-6 CAPLUS
CN Benzamide, 4-[[(2S)-tetrahydro-2-furanyl]methoxy]-N-[(2S)-1,2,3,4-tetrahydro-6-[[4-(1-hydroxy-1-methylethyl)-1-piperidinyl]methyl]-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119019-25-8 CAPLUS
CN Benzamide, N-[(2S)-6-[(3-fluoro-1-piperidinyl)methyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-4-[[(2S)-tetrahydro-2-furanyl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119019-41-8 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[[(6S)-5,6,7,8-tetrahydro-6-[[4-[[(2S)-tetrahydro-2-furanyl]methoxy]benzoyl]amino]-2-naphthalenyl]methyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 1119019-45-2 CAPLUS
CN Benzamide, 4-[[(2S)-tetrahydro-2-furanyl]methoxy]-N-[(2S)-1,2,3,4-tetrahydro-6-[(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-ylmethyl]-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119019-47-4 CAPLUS
CN Benzamide, 4-[[(2S)-tetrahydro-2-furanyl]methoxy]-N-[(2S)-1,2,3,4-tetrahydro-6-[[3-(methylsulfonyl)-1-pyrrolidinyl]methyl]-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119019-67-8 CAPLUS
CN Benzamide, N-[(2S)-6-(1,4-dioxa-8-azaspiro[4.5]dec-8-ylmethyl)-1,2,3,4-tetrahydro-2-naphthalenyl]-4-[[(2S)-tetrahydro-2-furanyl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119019-71-4 CAPLUS
CN Benzamide, N-[(2S)-6-[(2,6-dimethyl-1-piperidinyl)methyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-4-[[(2S)-tetrahydro-2-furanyl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119019-83-8 CAPLUS
CN Benzamide, 4-[[(2S)-tetrahydro-2-furanyl]methoxy]-N-[(2S)-1,2,3,4-tetrahydro-6-[(3-methoxy-1-pyrrolidinyl)methyl]-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119019-89-4 CAPLUS
CN Benzamide, N-[(2S)-6-[(5,6-dihydro-1,2,4-triazolo[4,3-a]pyrazin-7(8H)-yl)methyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-4-[[(2S)-tetrahydro-2-furanyl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.



IT 1119016-66-8P 1119016-68-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tetrahydronaphthalenes as antidiabetic agents)
RN 1119016-66-8 CAPLUS
CN Benzamide, 4-[[(2S)-tetrahydro-2-furanyl]methoxy]-N-[(2S)-1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1119016-68-0 CAPLUS
CN Benzamide, 4-[[(2S)-tetrahydro-2-furanyl]methoxy]-N-[(2S)-1,2,3,4-tetrahydro-6-[1-(1-pyrrolidinyl)ethyl]-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 1119020-01-7P 1119020-11-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of tetrahydronaphthalenes as antidiabetic agents)
RN 1119020-01-7 CAPLUS
CN Carbamic acid, N-[(2S)-1,2,3,4-tetrahydro-6-(1-pyrrolidinylcarbonyl)-2-naphthalenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 1119020-11-9 CAPLUS
CN 2-Naphthalenamine, 1,2,3,4-tetrahydro-N-methyl-6-(1-pyrrolidinylmethyl)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:1136462 CAPLUS
DOCUMENT NUMBER: 149:515197
TITLE: Syntheses of a Triad of Flt3 Kinase Inhibitors: From Bench to Pilot Plant
AUTHOR(S): Shieh, Wen-Chung; McKenna, Joe; Sclafani, Joseph A.; Xue, Song; Girgis, Michael; Vivelo, James; Radetich, Branko; Prasad, Kapa
CORPORATE SOURCE: Chemical and Analytical Development, Novartis Pharmaceuticals Corporation, East Hanover, NJ, 07936, USA
SOURCE: Organic Process Research & Development (2008), 12(6), 1146-1155
CODEN: OPRDFK; ISSN: 1083-6160
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 149:515197

AB We have designed and developed an alternative synthesis for the manufacturing of a triad of Flt3 kinase inhibitors (AST487, ATH686, and AUZ454) to support clin. assessments of patients with Flt3-dependent tumor diseases. The new synthesis is convergent, environmentally friendly, practical, and safe and requires no chromatog. purification

IT 1069112-54-4P
RL: IMF (Industrial manufacture); PREP (Preparation)
(syntheses of triad of Flt3 Kinase inhibitors)
RN 1069112-54-4 CAPLUS
CN Urea, N-[4-[[6-amino-2-(methylamino)-4-pyrimidinyl]oxy]phenyl]-N'-[6-[(4-ethyl-1-piperazinyl)methyl]-1,2,3,4-tetrahydro-7-(trifluoromethyl)-2-naphthalenyl]- (CA INDEX NAME)



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:10661 CAPLUS
DOCUMENT NUMBER: 148:100397
TITLE: Preparation of substituted naphthalene amides as melanin concentrating hormone antagonists for disease treatment
INVENTOR(S): Hu, Xiufeng Eric
PATENT ASSIGNEE(S): The Procter & Gamble Company, USA
SOURCE: PCT Int. Appl., 79pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008001160	A1	20080103	WO 2006-IB52069	20060623

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: WO 2006-IB52069 20060623
OTHER SOURCE(S): CASREACT 148:100397; MARPAT 148:100397
GI



II

AB The present invention relates to compds. of general formula I (wherein J is a substituted phenylpyridinyl; R is a disubstituted amino; L1 is a

linking group; R5 is H or Me) capable of serving as moderators of human and mammalian appetite and as such provides a means for reducing body mass. The compds. of the present invention are selective against melanin concentrating hormone and do not have the pernicious side effects resulting from
compds. which interact with other appetite related brain receptors. Synthesis of I is exemplified. Example compound II was prepared by reacting 6-[(dimethylamino)methyl]-N-methyl-1,2,3,4-tetrahydronaphthalen-2-amine (preparation given) and 6-(4-fluorophenyl)nicotinic acid. In an in vitro assay, II has an IC50 of 184nM at the MCH1R receptor.

IT 849420-80-0P 849420-99-1P 913712-07-9P
913712-09-1P 913712-13-7P 913712-29-5P
913712-30-8P 913712-31-9P 913712-32-0P
913712-33-1P 913712-37-5P 1000161-40-9P
1000161-42-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of substituted naphthalene amides as melanin concentrating hormone antagonists for disease treatment)

RN 849420-80-0 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-fluoro-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 849420-99-1 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-fluoro-N-methyl-N-[(2S)-1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 913712-07-9 CAPLUS
CN 2-Pyridinecarboxamide, 5-(4-fluorophenyl)-N-methyl-N-[1,2,3,4-tetrahydro-6-[(3-hydroxy-1-pyrrolidinyl)methyl]-2-naphthalenyl]- (CA INDEX NAME)



RN 913712-09-1 CAPLUS
CN 2-Pyridinecarboxamide, 5-(2-fluorophenyl)-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 913712-13-7 CAPLUS
CN 2-Pyridinecarboxamide, 5-(2-fluorophenyl)-N-methyl-N-[1,2,3,4-tetrahydro-6-[[4-(2-oxo-1-pyrrolidinyl)-1-piperidinyl]methyl]-2-naphthalenyl]- (CA INDEX NAME)



RN 913712-29-5 CAPLUS
CN 2-Pyrrolidineacetic acid, 1-[[6-[[[5-(4-chlorophenyl)-2-pyridinyl]carbonyl]methylamino]-5,6,7,8-tetrahydro-2-naphthalenyl]methyl]-, methyl ester (CA INDEX NAME)



RN 913712-30-8 CAPLUS
CN 2-Pyridinecarboxamide, 5-(4-chlorophenyl)-N-[6-[[2-[2-(dimethylamino)-2-

oxoethyl]-1-pyrrolidinyl]methyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-N-methyl- (CA INDEX NAME)



RN 913712-31-9 CAPLUS
CN 2-Pyridinecarboxamide, 5-(4-chlorophenyl)-N-[1,2,3,4-tetrahydro-6-[[4-(2-oxo-1-pyrrolidinyl)-1-piperidinyl]methyl]-2-naphthalenyl]- (CA INDEX NAME)



RN 913712-32-0 CAPLUS
CN 2-Pyridinecarboxamide, 5-(3,4-dichlorophenyl)-N-methyl-N-[1,2,3,4-tetrahydro-6-[(3-hydroxy-1-pyrrolidinyl)methyl]-2-naphthalenyl]- (CA INDEX NAME)



RN 913712-33-1 CAPLUS
CN 2-Pyridinecarboxamide, 5-(3,4-dichlorophenyl)-N-methyl-N-[1,2,3,4-tetrahydro-6-[(3-hydroxy-1-piperidinyl)methyl]-2-naphthalenyl]- (CA INDEX NAME)



RN 913712-37-5 CAPLUS
CN 2-Pyridinecarboxamide, 5-(4-chlorophenyl)-N-methyl-N-[1,2,3,4-tetrahydro-6-

(2-oxa-5-azabicyclo[2.2.1]hept-5-ylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1000161-40-9 CAPLUS
CN 2-Pyridinecarboxamide, 5-(2-fluorophenyl)-N-[1,2,3,4-tetrahydro-6-[[4-(2-oxo-1-pyrrolidinyl)-1-piperidinyl]methyl]-2-naphthalenyl]- (CA INDEX NAME)



RN 1000161-42-1 CAPLUS
CN 2-Pyridinecarboxamide, 5-(2-chlorophenyl)-N-[1,2,3,4-tetrahydro-6-[[4-(2-oxo-1-pyrrolidinyl)-1-piperidinyl]methyl]-2-naphthalenyl]- (CA INDEX NAME)



IT 849420-79-7P 849420-81-1P 849421-00-7P
849421-01-8P 1008378-39-9P 1008378-41-3P
1008378-45-7P 1008378-50-4P 1008378-52-6P
1008378-55-9P 1008378-60-6P 1008378-62-8P
1008378-66-2P 1008378-73-1P 1008378-75-3P
1008378-77-5P 1008378-84-4P 1008378-86-6P
1008378-87-7P 1008378-96-8P 1008378-97-9P
1008378-99-1P 1008379-14-3P 1008379-15-4P
1008379-16-5P 1008379-24-5P 1008379-25-6P
1008379-28-9P 1008379-36-9P 1008379-39-2P
1008379-40-5P 1008379-48-3P 1008379-51-8P
1008379-53-0P 1008379-60-9P 1008379-62-1P
1008379-65-4P 1008381-09-6P 1008381-12-1P
1008381-14-3P 1008381-22-3P 1008381-24-5P
1008381-26-7P 1008381-34-7P 1008381-36-9P
1008381-37-0P 1008381-44-9P 1008381-45-0P

1008381-48-3P 1008381-55-2P 1008381-57-4P
1008381-58-5P 1008381-67-6P 1008381-70-1P
1008381-71-2P 1008381-78-9P 1008381-80-3P
1008381-82-5P 1008381-91-6P 1008381-92-7P
1008381-95-0P 1008382-02-2P 1008382-04-4P
1008382-07-7P 1008382-15-7P 1008382-16-8P
1008382-17-9P 1008382-23-7P 1008382-26-0P
1008382-27-1P 1008382-35-1P 1008382-38-4P
1008382-39-5P 1008383-87-6P 1008383-89-8P
1008383-91-2P 1008383-99-0P 1008384-00-6P
1008384-04-0P 1008384-09-5P 1008384-13-1P
1008384-14-2P 1008384-22-2P 1008384-24-4P
1008384-26-6P 1008384-33-5P 1008384-34-6P
1008384-35-7P 1008384-43-7P 1008384-45-9P
1008384-48-2P 1008384-56-2P 1008384-57-3P
1008384-60-8P 1008384-67-5P 1008384-69-7P
1008384-72-2P 1008384-78-8P 1008384-81-3P
1008384-82-4P 1008384-90-4P 1008384-91-5P
1008384-94-8P 1008385-01-0P 1008385-02-1P
1008385-05-4P 1008385-13-4P 1008385-14-5P
1008385-16-7P
RL: PAC (Pharmacological activity); PRPH (Prophetic); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted naphthalene amides as melanin concentrating hormone
antagonists for disease treatment)

RN 849420-79-7 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-fluoro-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 849420-81-1 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-fluoro-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 849421-00-7 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-fluoro-N-methyl-N-[(2S)-1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 849421-01-8 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-fluoro-N-methyl-N-[(2S)-1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1008378-39-9 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-fluoro-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008378-41-3 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-fluoro-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008378-45-7 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-fluoro-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008378-50-4 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-chloro-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008378-52-6 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-chloro-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008378-55-9 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-chloro-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008378-60-6 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]-3'-(trifluoromethyl)- (CA INDEX NAME)



RN 1008378-62-8 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]-3'-(trifluoromethyl)- (CA INDEX NAME)



RN 1008378-66-2 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]-3'-(trifluoromethyl)- (CA INDEX NAME)



RN 1008378-73-1 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-cyano-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008378-75-3 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-cyano-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008378-77-5 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-cyano-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008378-84-4 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-nitro-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008378-86-6 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-nitro-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008378-87-7 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-nitro-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008378-96-8 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-methoxy-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008378-97-9 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-methoxy-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008378-99-1 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-methoxy-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008379-14-3 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-chloro-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008379-15-4 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-chloro-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008379-16-5 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-chloro-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008379-24-5 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]-4'-(trifluoromethyl)- (CA INDEX NAME)



RN 1008379-25-6 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]-4'-(trifluoromethyl)- (CA INDEX NAME)



RN 1008379-28-9 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]-4'-(trifluoromethyl)- (CA INDEX NAME)



RN 1008379-36-9 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-cyano-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008379-39-2 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-cyano-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008379-40-5 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-cyano-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008379-48-3 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-nitro-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008379-51-8 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-nitro-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008379-53-0 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-nitro-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008379-60-9 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-methoxy-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008379-62-1 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-methoxy-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008379-65-4 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-methoxy-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008381-09-6 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-fluoro-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008381-12-1 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-fluoro-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008381-14-3 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-fluoro-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008381-22-3 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-chloro-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008381-24-5 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-chloro-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008381-26-7 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-chloro-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008381-34-7 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-methyl-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]-3'-(trifluoromethyl)- (CA INDEX NAME)



RN 1008381-36-9 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]-3'-(trifluoromethyl)- (CA INDEX NAME)



RN 1008381-37-0 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]-3'-(trifluoromethyl)- (CA INDEX NAME)



RN 1008381-44-9 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-cyano-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008381-45-0 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-cyano-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008381-48-3 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-cyano-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008381-55-2 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-methyl-3'-nitro-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008381-57-4 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-methyl-3'-nitro-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008381-58-5 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-methyl-3'-nitro-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008381-67-6 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-methoxy-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008381-70-1 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-methoxy-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008381-71-2 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-methoxy-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008381-78-9 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-fluoro-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008381-80-3 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-fluoro-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008381-82-5 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-fluoro-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008381-91-6 CAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, 4'-chloro-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008381-92-7 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-chloro-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008381-95-0 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-chloro-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008382-02-2 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-methyl-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]-4'-(trifluoromethyl)- (CA INDEX NAME)



RN 1008382-04-4 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]-4'-(trifluoromethyl)- (CA INDEX NAME)



RN 1008382-07-7 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]-4'-(trifluoromethyl)- (CA INDEX NAME)



RN 1008382-15-7 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-cyano-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008382-16-8 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-cyano-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008382-17-9 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-cyano-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008382-23-7 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-methyl-4'-nitro-N-[1,2,3,4-tetrahydro-6-

(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008382-26-0 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-methyl-4'-nitro-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008382-27-1 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-methyl-4'-nitro-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008382-35-1 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-methoxy-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008382-38-4 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-methoxy-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008382-39-5 CAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, 4'-methoxy-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008383-87-6 CAPLUS
CN 3-Pyridinecarboxamide, 6-(3-fluorophenyl)-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008383-89-8 CAPLUS
CN 3-Pyridinecarboxamide, 6-(3-fluorophenyl)-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008383-91-2 CAPLUS
CN 3-Pyridinecarboxamide, 6-(3-fluorophenyl)-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008383-99-0 CAPLUS
CN 3-Pyridinecarboxamide, 6-(3-chlorophenyl)-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008384-00-6 CAPLUS
CN 3-Pyridinecarboxamide, 6-(3-chlorophenyl)-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008384-04-0 CAPLUS
CN 3-Pyridinecarboxamide, 6-(3-chlorophenyl)-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008384-09-5 CAPLUS
CN 3-Pyridinecarboxamide, N-methyl-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]-6-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 1008384-13-1 CAPLUS
CN 3-Pyridinecarboxamide, N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]-6-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 1008384-14-2 CAPLUS
CN 3-Pyridinecarboxamide, N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]-6-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 1008384-22-2 CAPLUS
CN 3-Pyridinecarboxamide, 6-(3-cyanophenyl)-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008384-24-4 CAPLUS
CN 3-Pyridinecarboxamide, 6-(3-cyanophenyl)-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008384-26-6 CAPLUS
CN 3-Pyridinecarboxamide, 6-(3-cyanophenyl)-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008384-33-5 CAPLUS
CN 3-Pyridinecarboxamide, N-methyl-6-(3-nitrophenyl)-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008384-34-6 CAPLUS
CN 3-Pyridinecarboxamide, N-methyl-6-(3-nitrophenyl)-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008384-35-7 CAPLUS
CN 3-Pyridinecarboxamide, N-methyl-6-(3-nitrophenyl)-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008384-43-7 CAPLUS
CN 3-Pyridinecarboxamide, 6-(3-methoxyphenyl)-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008384-45-9 CAPLUS
CN 3-Pyridinecarboxamide, 6-(3-methoxyphenyl)-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008384-48-2 CAPLUS
CN 3-Pyridinecarboxamide, 6-(3-methoxyphenyl)-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008384-56-2 CAPLUS
CN 3-Pyridinecarboxamide, 6-(4-fluorophenyl)-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008384-57-3 CAPLUS
CN 3-Pyridinecarboxamide, 6-(4-fluorophenyl)-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008384-60-8 CAPLUS
CN 3-Pyridinecarboxamide, 6-(4-fluorophenyl)-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008384-67-5 CAPLUS
CN 3-Pyridinecarboxamide, 6-(4-chlorophenyl)-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008384-69-7 CAPLUS
CN 3-Pyridinecarboxamide, 6-(4-chlorophenyl)-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008384-72-2 CAPLUS
CN 3-Pyridinecarboxamide, 6-(4-chlorophenyl)-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008384-78-8 CAPLUS
CN 3-Pyridinecarboxamide, N-methyl-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]-6-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 1008384-81-3 CAPLUS
CN 3-Pyridinecarboxamide, N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]-6-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 1008384-82-4 CAPLUS
CN 3-Pyridinecarboxamide, N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]-6-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 1008384-90-4 CAPLUS
CN 3-Pyridinecarboxamide, 6-(4-cyanophenyl)-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008384-91-5 CAPLUS
CN 3-Pyridinecarboxamide, 6-(4-cyanophenyl)-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008384-94-8 CAPLUS
CN 3-Pyridinecarboxamide, 6-(4-cyanophenyl)-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008385-01-0 CAPLUS
CN 3-Pyridinecarboxamide, N-methyl-6-(4-nitrophenyl)-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008385-02-1 CAPLUS
CN 3-Pyridinecarboxamide, N-methyl-6-(4-nitrophenyl)-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008385-05-4 CAPLUS
CN 3-Pyridinecarboxamide, N-methyl-6-(4-nitrophenyl)-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008385-13-4 CAPLUS
CN 3-Pyridinecarboxamide, 6-(4-methoxyphenyl)-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008385-14-5 CAPLUS
CN 3-Pyridinecarboxamide, 6-(4-methoxyphenyl)-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008385-16-7 CAPLUS
CN 3-Pyridinecarboxamide, 6-(4-methoxyphenyl)-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2007:82136 CAPLUS
DOCUMENT NUMBER: 146:243251
TITLE: Identification of a Nonpeptidic and Conformationally Restricted Bradykinin B1 Receptor Antagonist with Anti-Inflammatory Activity
AUTHOR(S): D'Amico, Derin C.; Aya, Toshi; Human, Jason; Fotsch, Christopher; Chen, Jian Jeffrey; Biswas, Kaustav; Riahi, Bobby; Norman, Mark H.; Willoughby, Christopher A.; Hungate, Randall; Reider, Paul J.; Biddlecome, Gloria; Lester-Zeiner, Dianna; Van Staden, Carlo; Johnson, Eileen; Kamassah, Augustus; Arik, Leyla; Wang, Judy; Viswanadhan, Vellarkad N.; Groneberg, Robert D.; Zhan, James; Suzuki, Hideo; Toro, Andras; Mareska, David A.; Clarke, David E.; Harvey, Darren M.; Burgess, Laurence E.; Laird, Ellen R.; Askew, Benny; Ng, Gordon
CORPORATE SOURCE: Chemistry Research and Development, Neuroscience, HTS/Molecular Pharmacology, Molecular Structure and Design, and Inflammation, Amgen Inc., Thousand Oaks, CA, 91320, USA
SOURCE: Journal of Medicinal Chemistry (2007), 50(4), 607-610
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 146:243251
GI



I

AB We report the discovery of chroman 28 (I), a potent and selective antagonist of human, nonhuman primate, rat, and rabbit bradykinin B1 receptors (0.4-17 nM). At 90 mg/kg s.c., 28 decreased plasma extravasation in two rodent models of inflammation. A novel method to calculate entropy is introduced and ascribed .apprx.30% of the gained affinity between "flexible" 4 (Ki = 132 nM) and "rigid" 28 (Ki = 0.77 nM) to decreased conformational entropy.
IT 784202-90-0
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

<12/04/2007> Erich Leese

(Biological study); USES (Uses)
(nonpeptidic antagonists of bradykinin B1 receptors)

RN 784202-90-0 CAPLUS

CN Benzenepropanamide, β-[(2-naphthalenylsulfonyl)amino]-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]-, (βR)- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT:	6	THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)
REFERENCE COUNT:	25	THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2007:81267 CAPLUS
DOCUMENT NUMBER: 146:220150
TITLE: Aminomethyl tetrahydronaphthalene biphenyl carboxamide MCH-R1 antagonists-Increasing selectivity over hERG
AUTHOR(S): Meyers, Kenneth M.; Kim, Nicholas; Mendez-Andino, Jose L.; Hu, X. Eric; Mumin, Rashid N.; Klopfenstein, Sean R.; Wos, John A.; Mitchell, Maria C.; Paris, Jennifer L.; Ackley, David C.; Holbert, Jerry K.; Mittelstadt, Scott W.; Reizes, Ofer
CORPORATE SOURCE: Procter & Gamble Pharmaceuticals, Mason, OH, 45039, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2007), 17(3), 814-818
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 146:220150
AB Aminomethyl tetrahydronaphthalene biphenyl carboxamide MCH-R1 antagonists with greater selectivity over hERG were identified. SAR studies addressing two distinct alternatives for structural modifications leading to improve hERG selectivity are described.
IT 925243-40-9P 925243-49-8P 925243-53-4P
925243-56-7P 925243-61-4P 925243-65-8P
925243-72-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(aminomethyl tetrahydronaphthalene biphenyl carboxamide MCH-R1 antagonists)
RN 925243-40-9 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[[(6S)-6-[[(4'-fluoro[1,1'-biphenyl]-4-yl)carbonyl]methylamino]-5,6,7,8-tetrahydro-2-naphthalenyl]methyl]-N,N-dimethyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 925243-49-8 CAPLUS
CN 1-Piperazinecarboxamide, 4-[[(6S)-6-[[(4'-fluoro[1,1'-biphenyl]-4-yl)carbonyl]methylamino]-5,6,7,8-tetrahydro-2-naphthalenyl]methyl]- (CA

INDEX NAME)

Absolute stereochemistry.



RN 925243-53-4 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-fluoro-N-methyl-N-[(2S)-1,2,3,4-tetrahydro-6-[(3-oxo-1-piperazinyl)methyl]-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 925243-56-7 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[(2S)-6-[(4-acetyl-1-piperazinyl)methyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-4'-fluoro-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 925243-61-4 CAPLUS

CN 2-Pyridinecarboxamide, N-[(2S)-6-[(4-acetyl-1-piperazinyl)methyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-5-(4-fluorophenyl)-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 925243-65-8 CAPLUS
CN Benzamide, N-[(2S)-6-[(4-acetyl-1-piperazinyl)methyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-N-methyl-4-(2-pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 925243-72-7 CAPLUS
CN 3-Pyridinecarboxamide, 6-(4-fluorophenyl)-N-methyl-N-[(2S)-1,2,3,4-tetrahydro-6-[(3-oxo-1-piperazinyl)methyl]-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD

(5 CITINGS)

REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2006:1150652 CAPLUS
DOCUMENT NUMBER: 145:471262
TITLE: Biarylcarboxamide as melanin concentrating hormone antagonists and their preparation, pharmaceutical compositions and use in the treatment of melanin concentrating hormone related diseases
INVENTOR(S): Hu, Xiufeng Eric
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 29pp., Cont.-in-part of U.S. Ser. No. 949,841.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 20060247239	A1	20061102	US 2006-473478		20060623
US 20050075324	A1	20050407	US 2004-949841		20040924
US 7304065	B2	20071204			
AU 2004278352	A1	20050414	AU 2004-278352		20040924
AU 2004278352	B2	20081030			
CA 2540826	A1	20050414	CA 2004-2540826		20040924
EP 1667958	A2	20060614	EP 2004-789086		20040924
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR					
BR 2004015051	A	20061128	BR 2004-15051		20040924
JP 2007508303	T	20070405	JP 2006-533994		20040924
CN 101068773	A	20071107	CN 2004-80028448		20040924
IN 2006DN01624	A	20070817	IN 2006-DN1624		20060324
ZA 2006002499	A	20070328	ZA 2006-2499		20060327
KR 2006060047	A	20060602	KR 2006-706228		20060330
MX 2006003654	A	20060605	MX 2006-3654		20060331
NO 2006001953	A	20060613	NO 2006-1953		20060502
PRIORITY APPLN. INFO.:			US 2003-507773P	P	20031001
			US 2004-536640P	P	20040115
			US 2004-949841	A2	20040924
			WO 2004-US31631	W	20040924

OTHER SOURCE(S): CASREACT 145:471262; MARPAT 145:471262
GI



I



II

AB The invention relates to compds. of formula I, which are capable of serving as moderators of human and mammalian appetite and as such provides a means for reducing body mass. The compds. of the invention are selective against melanin concentrating hormone and do not have the pernicious side effects resulting from compds. which interact with other appetite related brain receptors. Compds. of formula I wherein H is (un)substituted phenylpyridinyl; R is NH2 and derivs.; L 1 is CH2, CH(CH3), and C(CH3)2; R5 is H and Me; and their enantiomers, diastereoisomers, and pharmaceutically acceptable salts thereof are claimed. Example compound II was prepared by amidation of 4'-fluorophenyl-4-benzoic acid with 6-bromo-1,2,3,4-tetrahydronaphthalen-2-ylamine trifluoroacetate; the resulting 4'-fluorobiphenyl-4-carboxylic acid (6-bromo-1,2,3,4-tetrahydronaphthalen-2-yl) amide underwent substitution to give 4'-fluorobiphenyl-4-carboxylic acid (6-cyano-1,2,3,4-tetrahydronaphthalen-2-yl) amide, which underwent reduction to give compound II. All the invention compds. were evaluated for their MCH1R and 5-HT2c receptor binding affinities (data given).

IT 849420-79-7 849420-81-1 1008378-39-9
1008378-41-3 1008378-45-7 1008378-50-4
1008378-52-6 1008378-55-9 1008378-60-6
1008378-62-8 1008378-66-2 1008378-73-1
1008378-75-3 1008378-77-5 1008378-84-4
1008378-86-6 1008378-87-7 1008378-96-8
1008378-97-9 1008378-99-1 1008379-14-3
1008379-15-4 1008379-16-5 1008379-24-5
1008379-25-6 1008379-28-9 1008379-36-9
1008379-39-2 1008379-40-5 1008379-48-3
1008379-51-8 1008379-53-0 1008379-60-9
1008379-62-1 1008379-65-4 1008381-09-6
1008381-12-1 1008381-14-3 1008381-22-3
1008381-24-5 1008381-26-7 1008381-34-7
1008381-36-9 1008381-37-0 1008381-44-9
1008381-45-0 1008381-48-3 1008381-55-2
1008381-57-4 1008381-58-5 1008381-67-6

1008381-70-1 1008381-71-2 1008381-78-9
1008381-80-3 1008381-82-5 1008381-91-6
1008381-92-7 1008381-95-0 1008382-02-2
1008382-04-4 1008382-07-7 1008382-15-7
1008382-16-8 1008382-17-9 1008382-23-7
1008382-26-0 1008382-27-1 1008382-35-1
1008382-38-4 1008382-39-5 1008383-87-6
1008383-89-8 1008383-91-2 1008383-99-0
1008384-00-6 1008384-04-0 1008384-09-5
1008384-13-1 1008384-14-2 1008384-22-2
1008384-24-4 1008384-26-6 1008384-33-5
1008384-34-6 1008384-35-7 1008384-43-7
1008384-45-9 1008384-48-2 1008384-56-2
1008384-57-3 1008384-60-8 1008384-67-5
1008384-69-7 1008384-72-2 1008384-78-8
1008384-81-3 1008384-82-4 1008384-90-4
1008384-91-5 1008384-94-8 1008385-01-0
1008385-02-1 1008385-05-4 1008385-13-4
1008385-14-5 1008385-16-7

RL: PRPH (Prophetic)
(Biarylcarboxamide as melanin concentrating hormone antagonists and their preparation, pharmaceutical compositions and use in the treatment of melanin concentrating hormone related diseases)

RN 849420-79-7 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-fluoro-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 849420-81-1 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-fluoro-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008378-39-9 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-fluoro-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008378-41-3 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-fluoro-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008378-45-7 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-fluoro-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008378-50-4 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-chloro-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008378-52-6 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-chloro-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008378-55-9 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-chloro-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008378-60-6 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]-3'-(trifluoromethyl)- (CA INDEX NAME)



RN 1008378-62-8 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]-3'-(trifluoromethyl)- (CA INDEX NAME)



RN 1008378-66-2 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]-3'-(trifluoromethyl)- (CA INDEX NAME)



RN 1008378-73-1 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-cyano-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008378-75-3 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-cyano-N-[1,2,3,4-tetrahydro-6-(1-

piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008378-77-5 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-cyano-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008378-84-4 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-nitro-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008378-86-6 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-nitro-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008378-87-7 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-nitro-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008378-96-8 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-methoxy-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008378-97-9 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-methoxy-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008378-99-1 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-methoxy-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008379-14-3 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-chloro-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008379-15-4 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-chloro-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008379-16-5 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-chloro-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008379-24-5 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]-4'-(trifluoromethyl)- (CA INDEX NAME)



RN 1008379-25-6 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]-4'-(trifluoromethyl)- (CA INDEX NAME)



RN 1008379-28-9 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]-4'-(trifluoromethyl)- (CA INDEX NAME)



RN 1008379-36-9 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-cyano-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008379-39-2 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-cyano-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008379-40-5 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-cyano-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008379-48-3 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-nitro-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008379-51-8 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-nitro-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008379-53-0 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-nitro-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008379-60-9 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-methoxy-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008379-62-1 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-methoxy-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008379-65-4 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-methoxy-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008381-09-6 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-fluoro-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008381-12-1 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-fluoro-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008381-14-3 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-fluoro-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008381-22-3 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-chloro-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008381-24-5 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-chloro-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008381-26-7 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-chloro-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008381-34-7 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-methyl-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]-3'-(trifluoromethyl)- (CA INDEX NAME)



RN 1008381-36-9 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]-3'-(trifluoromethyl)- (CA INDEX NAME)



RN 1008381-37-0 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]-3'-(trifluoromethyl)- (CA INDEX NAME)



RN 1008381-44-9 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-cyano-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008381-45-0 CAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, 3'-cyano-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008381-48-3 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-cyano-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008381-55-2 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-methyl-3'-nitro-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008381-57-4 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-methyl-3'-nitro-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008381-58-5 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-methyl-3'-nitro-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008381-67-6 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-methoxy-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008381-70-1 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-methoxy-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008381-71-2 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-methoxy-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008381-78-9 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-fluoro-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008381-80-3 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-fluoro-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008381-82-5 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-fluoro-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008381-91-6 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-chloro-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008381-92-7 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-chloro-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008381-95-0 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-chloro-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008382-02-2 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-methyl-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]-4'-(trifluoromethyl)- (CA INDEX NAME)



RN 1008382-04-4 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]-4'-(trifluoromethyl)- (CA INDEX NAME)



RN 1008382-07-7 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]-4'-(trifluoromethyl)- (CA INDEX NAME)



RN 1008382-15-7 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-cyano-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008382-16-8 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-cyano-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008382-17-9 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-cyano-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008382-23-7 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-methyl-4'-nitro-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008382-26-0 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-methyl-4'-nitro-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008382-27-1 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-methyl-4'-nitro-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008382-35-1 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-methoxy-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008382-38-4 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-methoxy-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008382-39-5 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-methoxy-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008383-87-6 CAPLUS
CN 3-Pyridinecarboxamide, 6-(3-fluorophenyl)-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008383-89-8 CAPLUS
CN 3-Pyridinecarboxamide, 6-(3-fluorophenyl)-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008383-91-2 CAPLUS
CN 3-Pyridinecarboxamide, 6-(3-fluorophenyl)-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008383-99-0 CAPLUS
CN 3-Pyridinecarboxamide, 6-(3-chlorophenyl)-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008384-00-6 CAPLUS
CN 3-Pyridinecarboxamide, 6-(3-chlorophenyl)-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008384-04-0 CAPLUS
CN 3-Pyridinecarboxamide, 6-(3-chlorophenyl)-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008384-09-5 CAPLUS
CN 3-Pyridinecarboxamide, N-methyl-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]-6-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 1008384-13-1 CAPLUS
CN 3-Pyridinecarboxamide, N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]-6-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 1008384-14-2 CAPLUS
CN 3-Pyridinecarboxamide, N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]-6-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 1008384-22-2 CAPLUS
CN 3-Pyridinecarboxamide, 6-(3-cyanophenyl)-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008384-24-4 CAPLUS
CN 3-Pyridinecarboxamide, 6-(3-cyanophenyl)-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008384-26-6 CAPLUS
CN 3-Pyridinecarboxamide, 6-(3-cyanophenyl)-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008384-33-5 CAPLUS
CN 3-Pyridinecarboxamide, N-methyl-6-(3-nitrophenyl)-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008384-34-6 CAPLUS
CN 3-Pyridinecarboxamide, N-methyl-6-(3-nitrophenyl)-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008384-35-7 CAPLUS
CN 3-Pyridinecarboxamide, N-methyl-6-(3-nitrophenyl)-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008384-43-7 CAPLUS
CN 3-Pyridinecarboxamide, 6-(3-methoxyphenyl)-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008384-45-9 CAPLUS
CN 3-Pyridinecarboxamide, 6-(3-methoxyphenyl)-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008384-48-2 CAPLUS
CN 3-Pyridinecarboxamide, 6-(3-methoxyphenyl)-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008384-56-2 CAPLUS
CN 3-Pyridinecarboxamide, 6-(4-fluorophenyl)-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008384-57-3 CAPLUS
CN 3-Pyridinecarboxamide, 6-(4-fluorophenyl)-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008384-60-8 CAPLUS
CN 3-Pyridinecarboxamide, 6-(4-fluorophenyl)-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008384-67-5 CAPLUS
CN 3-Pyridinecarboxamide, 6-(4-chlorophenyl)-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008384-69-7 CAPLUS
CN 3-Pyridinecarboxamide, 6-(4-chlorophenyl)-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008384-72-2 CAPLUS
CN 3-Pyridinecarboxamide, 6-(4-chlorophenyl)-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008384-78-8 CAPLUS
CN 3-Pyridinecarboxamide, N-methyl-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]-6-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 1008384-81-3 CAPLUS
CN 3-Pyridinecarboxamide, N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]-6-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 1008384-82-4 CAPLUS
CN 3-Pyridinecarboxamide, N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]-6-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 1008384-90-4 CAPLUS
CN 3-Pyridinecarboxamide, 6-(4-cyanophenyl)-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008384-91-5 CAPLUS
CN 3-Pyridinecarboxamide, 6-(4-cyanophenyl)-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008384-94-8 CAPLUS
CN 3-Pyridinecarboxamide, 6-(4-cyanophenyl)-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008385-01-0 CAPLUS
CN 3-Pyridinecarboxamide, N-methyl-6-(4-nitrophenyl)-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008385-02-1 CAPLUS
CN 3-Pyridinecarboxamide, N-methyl-6-(4-nitrophenyl)-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008385-05-4 CAPLUS

CN 3-Pyridinecarboxamide, N-methyl-6-(4-nitrophenyl)-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008385-13-4 CAPLUS
CN 3-Pyridinecarboxamide, 6-(4-methoxyphenyl)-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008385-14-5 CAPLUS
CN 3-Pyridinecarboxamide, 6-(4-methoxyphenyl)-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008385-16-7 CAPLUS
CN 3-Pyridinecarboxamide, 6-(4-methoxyphenyl)-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



IT 849420-80-0P 849420-99-1P 913712-07-9P
913712-09-1P 913712-13-7P 913712-29-5P
913712-30-8P 913712-31-9P 913712-32-0P
913712-33-1P 913712-37-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of biarylcarboxamides as melanin concentrating hormone
antagonists)

RN 849420-80-0 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-fluoro-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 849420-99-1 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-fluoro-N-methyl-N-[(2S)-1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 913712-07-9 CAPLUS
CN 2-Pyridinecarboxamide, 5-(4-fluorophenyl)-N-methyl-N-[1,2,3,4-tetrahydro-6-[(3-hydroxy-1-pyrrolidinyl)methyl]-2-naphthalenyl]- (CA INDEX NAME)



RN 913712-09-1 CAPLUS
CN 2-Pyridinecarboxamide, 5-(2-fluorophenyl)-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 913712-13-7 CAPLUS
CN 2-Pyridinecarboxamide, 5-(2-fluorophenyl)-N-methyl-N-[1,2,3,4-tetrahydro-6-[[4-(2-oxo-1-pyrrolidinyl)-1-piperidinyl]methyl]-2-naphthalenyl]- (CA INDEX NAME)



RN 913712-29-5 CAPLUS
CN 2-Pyrrolidineacetic acid, 1-[[6-[[[5-(4-chlorophenyl)-2-pyridinyl]carbonyl]methylamino]-5,6,7,8-tetrahydro-2-naphthalenyl]methyl]-, methyl ester (CA INDEX NAME)



RN 913712-30-8 CAPLUS
CN 2-Pyridinecarboxamide, 5-(4-chlorophenyl)-N-[6-[[2-[2-(dimethylamino)-2-oxoethyl]-1-pyrrolidinyl]methyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-N-methyl- (CA INDEX NAME)



RN 913712-31-9 CAPLUS
CN 2-Pyridinecarboxamide, 5-(4-chlorophenyl)-N-[1,2,3,4-tetrahydro-6-[[4-(2-oxo-1-pyrrolidinyl)-1-piperidinyl]methyl]-2-naphthalenyl]- (CA INDEX NAME)



RN 913712-32-0 CAPLUS
CN 2-Pyridinecarboxamide, 5-(3,4-dichlorophenyl)-N-methyl-N-[1,2,3,4-tetrahydro-6-[(3-hydroxy-1-pyrrolidinyl)methyl]-2-naphthalenyl]- (CA INDEX NAME)



RN 913712-33-1 CAPLUS
CN 2-Pyridinecarboxamide, 5-(3,4-dichlorophenyl)-N-methyl-N-[1,2,3,4-tetrahydro-6-[(3-hydroxy-1-piperidinyl)methyl]-2-naphthalenyl]- (CA INDEX NAME)



RN 913712-37-5 CAPLUS
CN 2-Pyridinecarboxamide, 5-(4-chlorophenyl)-N-methyl-N-[1,2,3,4-tetrahydro-6-(2-oxa-5-azabicyclo[2.2.1]hept-5-ylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



L17 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:1132911 CAPLUS
DOCUMENT NUMBER: 143:405810
TITLE: Preparation of cyclic amine derivatives as bradykinin antagonists and their use in the treatment of pain and inflammation
INVENTOR(S): Groneberg, Robert D.; Zhan, James; Askew, Benny C.; D'Amico, Derin C.; Han, Nianhe; Fotsch, Christopher H.; Liu, Qingyian; Riahi, Babak; Zhu, Jiawang; Yang, Kevin; Chen, Jian Jeffrey; Nomak, Rana
PATENT ASSIGNEE(S): Amgen Inc., USA; Array Biopharma, Inc.
SOURCE: U.S. Pat. Appl. Publ., 107 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050234044	A1	20051020	US 2004-823372	20040412
US 7199244	B2	20070403		

PRIORITY APPLN. INFO.: US 2003-461673P P 20030410
OTHER SOURCE(S): MARPAT 143:405810
GI



I



II

AB Title compds. I [wherein X = (CH2)q; Y = (CH2)t; q = 0-3; t = 0-2; when t = 2, q is not 3; R = 9-11-membered fused bicyclic carbocyclic or heterocyclic ring substituted with 1 to 3 basic moieties, and optionally substituted with 1 to 3 groups independently selected from NH2, OH, CN,

oxo, alkoxy etc.; ; R2 = (un)substituted arylalkenyl, aryl, heterocyclyl selected from thienyl, imidazolyl, and benzo-fused heteroaryl; Ra = independently H, alkyl; and aryl optionally substituted with 1 to 3 groups independently selected from halo, OH, CN, alkylamino, alk(en/yn)yl, etc.; Rb = independently H, oxo, OH, benzyloxy, C1-2-alkyl; Rc = independently H, alkyl; or RbCCRc = 6-membered hetero/aryl optionally substituted with 1 to 3 groups independently selected from halo, OH, CN, CF3, oxo, alkoxy, alkylamino, alkenyl, etc.; and their pharmaceutically acceptable salts] were prepared as bradykinin antagonists. Seven biol. tests are given. For example, II•HCl was prepared by reductive amination of N-((R)-7-formylchroman-4-yl)-2-[1-(3-trifluoromethylbenzenesulfonyl)piperidin-2-yl]acetamide (preparation given) with piperidine in N,N-dimethylacetamide in the presence of NaBH(OAc)3. Selected I bound to hB1 bradykinin receptor with IC50 values < 100 nm in an in vitro assay using calcium flux. Thus, I are useful for prophylaxis and treatment of diseases and other maladies or conditions involving pain, inflammation mediated by Bradykinin.

IT 783239-08-7P, [6-[(Piperidin-1-yl)methyl]-1,2,3,4-tetrahydronaphthalen-2-yl]carbamic acid tert-butyl ester
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of cyclic amine derivs. as bradykinin antagonists and their use in treatment of pain and inflammation)

RN 783239-08-7 CAPLUS

CN Carbamic acid, [1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:979643 CAPLUS
DOCUMENT NUMBER: 143:266686
TITLE: Preparation of tetralin derivatives as histamine H3 receptor antagonists
INVENTOR(S): Beavers, Lisa Selsam; Gadski, Robert Alan; Hipskind, Philip Arthur; Jesudason, Cynthia Darshini; Lindsley, Craig William; Lobb, Karen Lynn; Pickard, Richard Todd
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 49 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005082893	A2	20050909	WO 2005-US5491	20050222
WO 2005082893	A3	20060420		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1720861	A2	20061115	EP 2005-723430	20050222
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
US 20070155754	A1	20070705	US 2006-598262	20060823
PRIORITY APPLN. INFO.:			US 2004-547758P P	20040225
			WO 2005-US5491 W	20050222

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): CASREACT 143:266686; MARPAT 143:266686
GI



I



II

AB Tetralins of formula I [R1 = CH2NR3R4, CONR3R4, N-methylpiperazinocarbonyl; R2 = H, NH-alkyl, NR3R4, NH-cycloalkyl, N-methylpiperazino, piperidino, pyrrolidino, etc.; R3 = H, alkyl; R4 = alkyl, phenylalkylene; R3R4 = alkylene, etc.] are prepared which have histamine-H3 receptor antagonist activity. The invention discloses pharmaceutical compns. comprising compds. of formula I as well as methods of using them to treat obesity and other histamine H3 receptor-related diseases. Thus, II was prepared and had Ki value of 1.5 nM against GTP γ[35S].

IT 863925-20-6P 863925-21-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tetralin derivs. as histamine H3 receptor antagonists)

RN 863925-20-6 CAPLUS
CN Methanone, [(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl][5,6,7,8-tetrahydro-6-[(phenylmethyl)amino]-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 863925-21-7 CAPLUS
CN Methanone, [6-(butylamino)-5,6,7,8-tetrahydro-2-naphthalenyl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:540574 CAPLUS
DOCUMENT NUMBER: 143:78209
TITLE: Preparation of piperazinylethylindanes as dopamine D2 and serotonin 5-HT2A antagonists.
INVENTOR(S): Graham, James Michael; Kornberg, Brian Edward; Nikam, Cham Shridhar; Xie, Dejian
PATENT ASSIGNEE(S): Warner-Lambert Company LLC, USA
SOURCE: PCT Int. Appl., 132 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005056540	A1	20050623	WO 2004-IB3898	20041126
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2548447	A1	20050623	CA 2004-2548447	20041126
EP 1697334	A1	20060906	EP 2004-799000	20041126
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
BR 2004016739	A	20070116	BR 2004-16739	20041126
JP 2007513197	T	20070524	JP 2006-543635	20041126
NL 1027680	A1	20050609	NL 2004-1027680	20041207
NL 1027680	C2	20051130		
US 20050282819	A1	20051222	US 2004-7486	20041208
MX 2006006033	A	20060725	MX 2006-6033	20060526

PRIORITY APPLN. INFO.:	US 2003-527852P	P	20031208
	US 2003-531096P	P	20031219
	US 2003-531096	A	20031219
	US 2003-753096P	P	20031219
	WO 2004-IB3898	W	20041126

OTHER SOURCE(S): CASREACT 143:78209; MARPAT 143:78209
GI



I



II

AB Title compds. [I, II; J = S, SO, SO2, O, NR10; R10 = H, alkyl, alkylcarbonyl, alkoxycarbonyl; M, G = CH, N; m = 1-6; X = null, O, NR10, CHOH, CO, etc.; R1, R2 = H, halo, cyano, alkyl, fluoroalkyl, alkoxy, fluoroalkoxy; R1R10 = atoms to form heterocyclyl; R4, R5 = H, halo, cyano, (halo-substituted) aminoalkyl, alkylaminoalkyl, alkoxy, alkoxyalkyl, etc.; R6-R9 = H, alkyl, fluoroalkyl; Y = O, NR10, (CH2)w when R11 is present; w = 1-6; Y = O, OH, NR13R14, (CH2)qMe; n, z = 1-3; q = 1-5; R11 = null, H, (substituted) alkyl, alkylsulfonyl, arylsulfonyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, heterocyclyl, etc.; n+q ≤3; Q1 = (CR6R7)z; Q2 = (CR8R9)n], were prepared Thus, N-[5-(2-chloroethyl)indan-2-yl]-2,2,2-trifluoroacetamide (preparation given), 3-(piperazin-1-yl)benzo[d]isothiazole hydrochloride, and Na2CO3 were microwaved together in H2O at 175° for 10 min. to give N-[5-[2-(4-benzo[d]isothiazol-3-ylpiperazin-1-yl)ethyl]indan-2-yl]-2,2,2-trifluoroacetamide. Title compds. showed D2 and 5-HT2A binding with Ki ≤1 μM.

IT 855746-36-0P 855746-37-1P 855746-38-2P
855746-39-3P 855746-40-6P 855746-41-7P
855746-42-8P 855746-43-9P 855746-44-0P
855746-45-1P 855746-46-2P 855746-47-3P
855746-48-4P 855746-49-5P 855746-50-8P
855746-51-9P 855746-52-0P 855746-53-1P
855746-54-2P 855746-55-3P 855746-56-4P
855746-57-5P 855746-58-6P 855746-59-7P
855746-60-0P 855746-61-1P 855746-62-2P
855746-63-3P 855746-64-4P 855746-65-5P
855746-66-6P 855746-67-7P 855746-68-8P
855746-69-9P 855746-70-2P 855746-71-3P
855746-72-4P 855746-73-5P 855746-74-6P
855746-75-7P 855746-76-8P 855746-77-9P
855746-78-0P 855746-79-1P 855746-80-4P
855746-81-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of piperazinylethylindanes as dopamine D2 and serotonin 5-HT2A

antagonists)
RN 855746-36-0 CAPLUS
CN 2-Naphthalenamine, 6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,4-tetrahydro-N-methyl- (CA INDEX NAME)



RN 855746-37-1 CAPLUS
CN Acetamide, N-[6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-N-methyl- (CA INDEX NAME)



RN 855746-38-2 CAPLUS
CN Acetamide, N-[6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-, hydrochloride (5:7) (CA INDEX NAME)



● 7/5 HCl

RN 855746-39-3 CAPLUS
CN Propanamide, N-[6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 855746-40-6 CAPLUS
CN Butanamide, N-[6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-, hydrochloride (10:11) (CA INDEX NAME)



●11/10 HCl

RN 855746-41-7 CAPLUS
CN Butanamide, N-[6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-3-methyl-, hydrochloride (10:11) (CA INDEX NAME)



●11/10 HCl

RN 855746-42-8 CAPLUS
CN Cyclopentanecarboxamide, N-[6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-, hydrochloride (5:6) (CA INDEX NAME)



●6/5 HCl

RN 855746-43-9 CAPLUS
CN Cyclopropanecarboxamide, N-[6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-1-methyl- (CA INDEX NAME)



RN 855746-44-0 CAPLUS
CN Benzamide, N-[6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-2-fluoro- (CA INDEX NAME)



RN 855746-45-1 CAPLUS
CN 2-Furancarboxamide, N-[6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,4-tetrahydro-2-naphthalenyl]- (CA INDEX NAME)



RN 855746-46-2 CAPLUS
CN Pentanamide, N-[6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,4-tetrahydro-2-naphthalenyl]- (CA INDEX NAME)



RN 855746-47-3 CAPLUS
CN Benzamide, N-[6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-4-fluoro- (CA INDEX NAME)



RN 855746-48-4 CAPLUS
CN Benzamide, N-[6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,4-tetrahydro-2-naphthalenyl]- (CA INDEX NAME)



RN 855746-49-5 CAPLUS
CN Cyclopentaneacetamide, N-[6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,4-tetrahydro-2-naphthalenyl]- (CA INDEX NAME)



RN 855746-50-8 CAPLUS
CN Benzamide, N-[6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-3-fluoro- (CA INDEX NAME)



RN 855746-51-9 CAPLUS

CN Acetamide, N-[6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-2-methoxy- (CA INDEX NAME)



RN 855746-52-0 CAPLUS
CN Benzamide, N-[6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-4-methyl- (CA INDEX NAME)



RN 855746-53-1 CAPLUS
CN Benzeneacetamide, N-[6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,4-tetrahydro-2-naphthalenyl]- (CA INDEX NAME)



RN 855746-54-2 CAPLUS
CN Urea, N-[6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-N'-propyl- (CA INDEX NAME)



RN 855746-55-3 CAPLUS
CN Urea, N-[6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-N'-butyl- (CA INDEX NAME)



RN 855746-56-4 CAPLUS
CN Urea, N-[6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-N'-(1-methylethyl)- (CA INDEX NAME)



RN 855746-57-5 CAPLUS
CN Urea, N-[6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-N'-(phenylmethyl)- (CA INDEX NAME)



RN 855746-58-6 CAPLUS
CN Cyclopropanecarboxamide, N-[6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-N-methyl- (CA INDEX NAME)



RN 855746-59-7 CAPLUS
CN Propanamide, N-[6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-N-methyl- (CA INDEX NAME)



RN 855746-60-0 CAPLUS
CN Cyclopropanecarboxamide, N-[6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-N,1-dimethyl- (CA INDEX NAME)



RN 855746-61-1 CAPLUS
CN 3-Pyridinecarboxamide, N-[6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-N,6-dimethyl- (CA INDEX NAME)



RN 855746-62-2 CAPLUS
CN Benzamide, N-[6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-2-fluoro-N-methyl- (CA INDEX NAME)



RN 855746-63-3 CAPLUS
CN 2-Furancarboxamide, N-[6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-N-methyl- (CA INDEX NAME)



RN 855746-64-4 CAPLUS
CN Cyclohexanecarboxamide, N-[6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-N-methyl- (CA INDEX NAME)



RN 855746-65-5 CAPLUS
CN Butanamide, N-[6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-N,3-dimethyl- (CA INDEX NAME)



RN 855746-66-6 CAPLUS
CN Benzamide, N-[6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-N-methyl- (CA INDEX NAME)



RN 855746-67-7 CAPLUS
CN Cyclopentaneacetamide, N-[6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-N-methyl- (CA INDEX NAME)



RN 855746-68-8 CAPLUS
CN Benzamide, N-[6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-3-fluoro-N-methyl- (CA INDEX NAME)



RN 855746-69-9 CAPLUS
CN Acetamide, N-[6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-2-methoxy-N-methyl- (CA INDEX NAME)



RN 855746-70-2 CAPLUS
CN Butanamide, N-[6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-N-methyl- (CA INDEX NAME)



RN 855746-71-3 CAPLUS
CN Propanamide, N-[6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-N,2-dimethyl- (CA INDEX NAME)



RN 855746-72-4 CAPLUS
CN Butanamide, N-[6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-N,3,3-trimethyl- (CA INDEX NAME)



RN 855746-73-5 CAPLUS
CN Propanamide, N-[6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-N,2,2-trimethyl- (CA INDEX NAME)



RN 855746-74-6 CAPLUS
CN 2-Pyrazinecarboxamide, N-[6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-N-methyl- (CA INDEX NAME)



RN 855746-75-7 CAPLUS
CN Acetamide, N-[6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-2-(2-methoxyethoxy)-N-methyl- (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

— CH_2 — OMe

RN 855746-76-8 CAPLUS
CN Benzamide, N-[6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-N,4-dimethyl- (CA INDEX NAME)



RN 855746-77-9 CAPLUS
CN Urea, N-[6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-N-methyl-N'-propyl- (CA INDEX NAME)



RN 855746-78-0 CAPLUS
CN Urea, N-[6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-N'-butyl-N-methyl- (CA INDEX NAME)



RN 855746-79-1 CAPLUS
CN Urea, N-[6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-N-methyl-N'-(1-methylethyl)- (CA INDEX NAME)



RN 855746-80-4 CAPLUS
CN Urea, N-[6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-N-methyl-N'-(phenylmethyl)- (CA INDEX NAME)



RN 855746-81-5 CAPLUS
CN Acetamide, N-[6-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-2-hydroxy-N-methyl- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:304660 CAPLUS
DOCUMENT NUMBER: 142:373570
TITLE: Preparation of tetrahydronaphthalene derivatives as melanin concentrating hormone antagonists
INVENTOR(S): Hu, Xiufeng Eric
PATENT ASSIGNEE(S): The Procter & Gamble Company, USA
SOURCE: U.S. Pat. Appl. Publ., 28 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050075324	A1	20050407	US 2004-949841	20040924
US 7304065	B2	20071204		
AU 2004278352	A1	20050414	AU 2004-278352	20040924
AU 2004278352	B2	20081030		
CA 2540826	A1	20050414	CA 2004-2540826	20040924
WO 2005033063	A2	20050414	WO 2004-US31631	20040924
WO 2005033063	A3	20070322		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1667958	A2	20060614	EP 2004-789086	20040924
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004015051	A	20061128	BR 2004-15051	20040924
JP 2007508303	T	20070405	JP 2006-533994	20040924
CN 101068773	A	20071107	CN 2004-80028448	20040924
SG 146692	A1	20081030	SG 2008-7343	20040924
IN 2006DN01624	A	20070817	IN 2006-DN1624	20060324
ZA 2006002499	A	20070328	ZA 2006-2499	20060327
KR 2006060047	A	20060602	KR 2006-706228	20060330
MX 2006003654	A	20060605	MX 2006-3654	20060331
NO 2006001953	A	20060613	NO 2006-1953	20060502
US 20060247239	A1	20061102	US 2006-473478	20060623

PRIORITY APPLN. INFO.:	US 2003-507773P	P	20031001
	US 2004-536640P	P	20040115
	US 2004-949841	A2	20040924
	WO 2004-US31631	W	20040924

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): CASREACT 142:373570; MARPAT 142:373570
GI



I



II

AB The present invention relates to compds. I [R = NR1R2; R1, R2 = H, OH, (un)substituted, (un)branched, cyclic C1-8-alkyl, C2-8-alkenyl; NR1R2 = (un)substituted heterocyclic, heteroaryl 3- to 15-membered ring; L, L1 = linking groups, (Z)j(CR3aR3b)m(Z1)j(R4aR4b)n(Z2)j; Z, Z1, Z2 = NR5, O, SO2, NR5SO2, SO2NR5; j = 0, 1; R5 = H, linear, branched or cyclic C1-4-alkyl; R3a, R3b, R4a, R4b = H, OH, halogen, linear, branched or cyclic C1-4-alkyl, C1-4-haloalkyl, C1-4-alkoxy; CR3aR3b, CR4aR4b = C:X; X = O, S, NR5; m, n = 0 - 5; optionally, when m, n = 2 then R3bR3b, R4bR4b = bond; J = AB, especially, C6H4(C6H4Ra)-4; A, B = carbocyclic, aryl, heterocyclic, heteroaryl (with the proviso that at least one of A and B = aryl, heteroaryl); Ra = F, Cl, NO2, CN, OH, NH2, NMe2, OMe, NC(:O)Me, CO2R7, CF3, linear, branched or cyclic C1-4-alkyl; R7 = H, linear, branched or cyclic C1-10-alkyl], their enantiomers, stereoisomers and their pharmaceutically acceptable salts, capable of serving as moderators of human and mammalian appetite and as such provides a means for reducing body mass. Thus, 4'-fluoro-1,1'-biphenyl-4-carboxylic acid N-[(S)-6-(dimethylamino)methyl-1,2,3,4-tetrahydronaphthalen-2-yl]-N-methylamide (II) was prepared from 6-bromo-1,2,3,4-tetrahydronaphthalen-2-amine via reductive ammoniation with NH4OH in MeOH containing NaCNBH3, amidation of 4'-fluoro-1,1'-biphenyl-4-carboxylic acid in DMF containing EDCI, HOBT and Et3N, cyanation with Zn(CN)2 in NMP containing Et3Zn and catalytic Pd(OAc)2/P(C6H4Me-4)3, methylation with MeI in DMF containing NaH, reduction over Raney Ni in DMF containing NH4OH, dimethylation with HCHO in DMF containing NaBH(OAc)3 and isolation of the S enantiomer. The compds. of the present invention are selective against melanin concentrating hormone and do not have the pernicious side effects resulting from compds. which interact with other appetite related brain receptors. The melanin concentrating hormone antagonistic activity of II was determined [IC50 = 60 nM vs. MCH-1 receptor; IC50 = 100,000 nM vs. 5-HT2C receptor].

IT 1008378-39-9 1008378-41-3 1008378-45-7

1008378-50-4 1008378-52-6 1008378-55-9
1008378-60-6 1008378-62-8 1008378-66-2
1008378-73-1 1008378-75-3 1008378-77-5
1008378-84-4 1008378-86-6 1008378-87-7
1008378-96-8 1008378-97-9 1008378-99-1
1008379-14-3 1008379-15-4 1008379-16-5
1008379-24-5 1008379-25-6 1008379-28-9
1008379-36-9 1008379-39-2 1008379-40-5
1008379-48-3 1008379-51-8 1008379-53-0
1008379-60-9 1008379-62-1 1008379-65-4
1008381-09-6 1008381-12-1 1008381-14-3
1008381-22-3 1008381-24-5 1008381-26-7
1008381-34-7 1008381-36-9 1008381-37-0
1008381-44-9 1008381-45-0 1008381-48-3
1008381-55-2 1008381-57-4 1008381-58-5
1008381-67-6 1008381-70-1 1008381-71-2
1008381-78-9 1008381-80-3 1008381-82-5
1008381-91-6 1008381-92-7 1008381-95-0
1008382-02-2 1008382-04-4 1008382-07-7
1008382-15-7 1008382-16-8 1008382-17-9
1008382-23-7 1008382-26-0 1008382-27-1
1008382-35-1 1008382-38-4 1008382-39-5
RL: PRPH (Prophetic)
(Preparation of tetrahydronaphthalene derivatives as melanin concentrating hormone antagonists)

RN 1008378-39-9 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-fluoro-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008378-41-3 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-fluoro-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008378-45-7 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-fluoro-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008378-50-4 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-chloro-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008378-52-6 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-chloro-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008378-55-9 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-chloro-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008378-60-6 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]-3'-(trifluoromethyl)- (CA INDEX NAME)



RN 1008378-62-8 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]-3'-(trifluoromethyl)- (CA INDEX NAME)



RN 1008378-66-2 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]-3'-(trifluoromethyl)- (CA INDEX NAME)



RN 1008378-73-1 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-cyano-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008378-75-3 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-cyano-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008378-77-5 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-cyano-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008378-84-4 CAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, 3'-nitro-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008378-86-6 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-nitro-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008378-87-7 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-nitro-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008378-96-8 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-methoxy-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008378-97-9 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-methoxy-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008378-99-1 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-methoxy-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008379-14-3 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-chloro-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008379-15-4 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-chloro-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008379-16-5 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-chloro-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008379-24-5 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]-4'-(trifluoromethyl)- (CA INDEX NAME)



RN 1008379-25-6 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]-4'-(trifluoromethyl)- (CA INDEX NAME)



RN 1008379-28-9 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]-4'-(trifluoromethyl)- (CA INDEX NAME)



RN 1008379-36-9 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-cyano-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008379-39-2 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-cyano-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008379-40-5 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-cyano-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008379-48-3 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-nitro-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008379-51-8 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-nitro-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008379-53-0 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-nitro-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008379-60-9 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-methoxy-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008379-62-1 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-methoxy-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008379-65-4 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-methoxy-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008381-09-6 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-fluoro-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008381-12-1 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-fluoro-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008381-14-3 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-fluoro-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008381-22-3 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-chloro-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008381-24-5 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-chloro-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008381-26-7 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-chloro-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008381-34-7 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-methyl-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]-3'-(trifluoromethyl)- (CA INDEX NAME)



RN 1008381-36-9 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]-3'-(trifluoromethyl)- (CA INDEX NAME)



RN 1008381-37-0 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]-3'-(trifluoromethyl)- (CA INDEX NAME)



RN 1008381-44-9 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-cyano-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008381-45-0 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-cyano-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008381-48-3 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-cyano-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008381-55-2 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-methyl-3'-nitro-N-[1,2,3,4-tetrahydro-6-

(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008381-57-4 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-methyl-3'-nitro-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008381-58-5 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-methyl-3'-nitro-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008381-67-6 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-methoxy-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008381-70-1 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 3'-methoxy-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008381-71-2 CAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, 3'-methoxy-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008381-78-9 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-fluoro-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008381-80-3 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-fluoro-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008381-82-5 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-fluoro-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008381-91-6 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-chloro-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008381-92-7 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-chloro-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008381-95-0 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-chloro-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008382-02-2 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-methyl-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]-4'-(trifluoromethyl)- (CA INDEX NAME)



RN 1008382-04-4 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]-4'-(trifluoromethyl)- (CA INDEX NAME)



RN 1008382-07-7 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]-4'-(trifluoromethyl)- (CA INDEX NAME)



RN 1008382-15-7 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-cyano-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008382-16-8 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-cyano-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008382-17-9 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-cyano-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008382-23-7 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-methyl-4'-nitro-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008382-26-0 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-methyl-4'-nitro-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008382-27-1 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-methyl-4'-nitro-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008382-35-1 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-methoxy-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008382-38-4 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-methoxy-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 1008382-39-5 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-methoxy-N-methyl-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



IT 849420-79-7P 849420-80-0P 849420-81-1P

849420-99-1P 849421-00-7P 849421-01-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tetrahydronaphthalene derivs. as melanin concentrating hormone
antagonists)

RN 849420-79-7 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-fluoro-N-[1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 849420-80-0 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-fluoro-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 849420-81-1 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-fluoro-N-[1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)



RN 849420-99-1 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-fluoro-N-methyl-N-[(2S)-1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 849421-00-7 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-fluoro-N-methyl-N-[(2S)-1,2,3,4-tetrahydro-6-(1-piperazinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 849421-01-8 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-fluoro-N-methyl-N-[(2S)-1,2,3,4-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:58137 CAPLUS
DOCUMENT NUMBER: 142:155975
TITLE: Preparation of arylsufonyloxopiperazinylacetamides for treatment of inflammation and pain
INVENTOR(S): Chen, Jian J.; Askew, Ben C.; Biswas, Kaustav; Chau, Jennifer N.; D'Amico, Derin C.; Harried, Scott; Nguyen, Thomas; Qian, Wenyuan; Zhu, Jiawang; Fotsch, Christopher H.; Li, Aiwen; Liu, Qingyian; Nishimura, Nobuku; Peterkin, Tanya; Riahi, Babak; Yuan, Chester Chenguang; Han, Nianhe; Nomak, Rana; Yang, Kevin
PATENT ASSIGNEE(S): Amgen Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 98 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050014749	A1	20050120	US 2004-874086	20040621
US 7393852	B2	20080701		
AU 2004303757	A1	20050707	AU 2004-303757	20040621
AU 2004303757	B2	20090723		
CA 2529314	A1	20050707	CA 2004-2529314	20040621
WO 2005061467	A2	20050707	WO 2004-US19935	20040621
WO 2005061467	A3	20060601		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1656355	A2	20060517	EP 2004-820712	20040621
EP 1656355	B1	20080312		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004011673	A	20060808	BR 2004-11673	20040621
CN 1849121	A	20061018	CN 2004-80023752	20040621
JP 2007516176	T	20070621	JP 2006-517523	20040621
EP 1878728	A2	20080116	EP 2007-20439	20040621
EP 1878728	A3	20080130		
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, HR, LT, LV, MK				
AT 388708	T	20080315	AT 2004-820712	20040621
ES 2302079	T3	20080701	ES 2004-820712	20040621
MX 2005013469	A	20060309	MX 2005-13469	20051209
KR 2006036399	A	20060428	KR 2005-723864	20051212
NO 2006000278	A	20060315	NO 2006-278	20060119
ZA 2006000579	A	20070425	ZA 2006-579	20060120
US 20090054460	A1	20090226	US 2008-8696	20080111

PRIORITY APPLN. INFO.: US 2003-480303P P 20030620
EP 2004-820712 A3 20040621
US 2004-874086 A3 20040621
WO 2004-US19935 W 20040621
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): CASREACT 142:155975; MARPAT 142:155975
GI



I



II

AB Title compds. [I; p = 0-2; q = 0-3; X = O, S, imino; R = substituted (fused) carbocyclyl, carbocyclyl, heterocyclyl, aralkyl, heterocyclylalkyl, cycloalkyl, diphenylmethyl, etc.; R1 = H, (substituted) alkyl, aryl; RR1N = (substituted) Ph-fused heterocyclyl; R2 = (substituted) aralkenyl, aryl, heterocyclyl; R3, R3a, R4, R4a, R5, R5a = H, (substituted) alkyl; R3R3a, R4R4a, R5R5a = O; Rx = H, alkyl, haloalkyl; Q = (CR5R5a)q; Q1 = (CR3R3a)p; with provisos], were prepared Thus, title compound (II) (preparation given) inhibited human bradykinin B1 activity with IC50 <1 μM.
IT 828924-94-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of arylsufonyloxopiperazinylacetamides for treatment of inflammation and pain)
RN 828924-94-3 CAPLUS
CN 2-Piperazineacetamide, 1-[(4-chlorophenyl)sulfonyl]-3-oxo-N-[(2R)-1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 828926-70-1P 828926-97-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylsufonyloxopiperazinylacetamides for treatment of inflammation and pain)
RN 828926-70-1 CAPLUS
CN 2-Piperazineacetamide, 1-[(4-chlorophenyl)sulfonyl]-3-oxo-N-[(2R)-1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 828926-97-2 CAPLUS
CN 2-Piperazineacetamide, 1-[(4-chlorophenyl)sulfonyl]-5-oxo-N-[(2R)-1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 783239-08-7P, (6-(Piperidin-1-ylmethyl)-1,2,3,4-tetrahydro-naphthalen-2-yl)carbamic acid tert-butyl ester
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of arylsufonyloxopiperazinylacetamides for treatment of inflammation and pain)
RN 783239-08-7 CAPLUS
CN Carbamic acid, [1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:902374 CAPLUS
DOCUMENT NUMBER: 141:379814
TITLE: Preparation of cyclic amine derivatives as bradykinin antagonists and their use in the treatment of pain and inflammation
INVENTOR(S): Groneberg, Robert D.; Zhan, James; Askew, Ben; D'Amico, Derin; Han, Nianh; Fotsch, Christopher H.; Liu, Qinglan; Riahi, Babak; Zhu, Jiawang; Yang, Kevin; Chen, Jian J.; Nomak, Rana
PATENT ASSIGNEE(S): Amgen, Inc., USA; Array Biopharma, Inc.
SOURCE: PCT Int. Appl., 261 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004092164	A1	20041028	WO 2004-US11670	20040412
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2522084	A1	20041028	CA 2004-2522084	20040412
EP 1633743	A1	20060315	EP 2004-759563	20040412
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
JP 2006522835	T	20061005	JP 2006-510083	20040412
MX 2005010883	A	20060123	MX 2005-10883	20051010
PRIORITY APPLN. INFO.:			US 2003-461673P P	20030410
			WO 2004-US11670 W	20040412

OTHER SOURCE(S): CASREACT 141:379814; MARPAT 141:379814
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein X = (CH2)q; Y = (CH2)t; q = 0-3; t = 0-2; when t = 2, q is not 3; R = 9-11-membered fused bicyclic carbocyclic or heterocyclic ring substituted with 1 to 3 basic moieties, and optionally substituted with 1 to 3 groups independently selected from NH2, OH, CN, oxo, alkoxy etc.; ; R2 = (un)substituted arylalkenyl, aryl, heterocyclyl selected from thienyl, imidazolyl, and benzofused heteroaryl; Ra = independently H, alkyl; and aryl optionally substituted with 1 to 3 groups independently selected from halo, OH, CN, alkylamino, alk(en/yn)yl, etc.; Rb = independently H, oxo, OH, benzyloxy, C1-2-alkyl; Rc = independently

H, alkyl; or RbCCRc = 6-membered hetero/aryl optionally substituted with 1 to 3 groups independently selected from halo, OH, CN, CF3, oxo, alkoxy, alkylamino, alkenyl, etc.; and their pharmaceutically acceptable salts] were prepared as bradykinin antagonists. Seven biol. tests are given. For example, II•HCl was prepared by reductive amination of aldehyde III (preparation given) with piperidine in N,N-dimethylacetamide in the presence of NaBH(OAc)3. Selected I bound to hB1 bradykinin receptor with IC50 values < 100 nm in an in vitro assay using calcium flux. Thus, I are useful for prophylaxis and treatment of diseases and other maladies or conditions involving pain, inflammation mediated by Bradykinin.

IT 783239-08-7P, [6-[(Piperidin-1-yl)methyl]-1,2,3,4-tetrahydronaphthalen-2-yl]carbamic acid tert-butyl ester
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of cyclic amine derivs. as bradykinin antagonists and their use in treatment of pain and inflammation)

RN 783239-08-7 CAPLUS

CN Carbamic acid, [1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



OS.CITING REF COUNT: 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS RECORD (10 CITINGS)

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:902334 CAPLUS
DOCUMENT NUMBER: 141:395300
TITLE: Preparation of N-bicyclyl-3-[[(hetero)arylsulfonyl]amino]-3-(hetero)arylpropionamides as bradykinin receptor modulators for treatment of pain, inflammation, and other conditions
INVENTOR(S): Groneberg, Robert D.; Askew, Ben; D'Amico, Derin; Zhan, James; Toro, Andras; Suzuki, Hideo; Mareska, David A.; Han, Nianh; Fotsch, Christopher H.; Liu, Qinglan; Riahi, Babak; Yang, Kevin; Li, Aiwan; Yuan, Chester; Biswas, Kaustav; Harried, Scott; Nguyen, Tom; Qian, Wenyuan; Chen, Jian J.; Nomak, Rana
PATENT ASSIGNEE(S): Amgen, Inc., USA; Array Biopharma, Inc.
SOURCE: PCT Int. Appl., 375 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004092116	A1	20041028	WO 2004-US11105	20040412
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004231070	A1	20041028	AU 2004-231070	20040412
AU 2004231070	B2	20080214		
CA 2521937	A1	20041028	CA 2004-2521937	20040412
US 20050124654	A1	20050609	US 2004-823377	20040412
US 7425631	B2	20080916		
EP 1631542	A1	20060308	EP 2004-759403	20040412
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
JP 2006522825	T	20061005	JP 2006-509895	20040412
MX 2005010884	A	20070115	MX 2005-10884	20051010
US 20090048224	A1	20090219	US 2008-205616	20080905

PRIORITY APPLN. INFO.:	US 2003-461888P	P	20030410
	US 2004-823377	A3	20040412
	WO 2004-US11105	W	20040412

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 141:395300
GI



I



II

AB Title compds. I [wherein R = (un)substituted bicyclic carbocyclic or heterocyclic ring; R1 = (un)substituted cycloalkyl, aryl(alkyl), heteroaryl, heterocyclyl; R2 = (un)substituted aryl(alkenyl), heterocyclyl, heteroaryl; Ra = independently H, NH2COCH2, alkyl, (un)substituted aryl; and pharmaceutically acceptable derivs. thereof] were prepared as bradykinin receptor ligands. For example, N-(7-formylchroman-4-yl)-3-(naphth-2-ylsulfonylamino)-3-phenylpropionamide (7-step preparation given) was condensed with piperidine in the presence of NaBH(OAc)3 in N,N-dimethylacetamide and precipitated to give II•HCl. In a radioligand binding assay, the latter showed affinity for the human B1 and human B2 bradykinin receptors with Ki values of <100 nM and >1 μM, resp. Selected compds. of the invention are effective for treatment of pain and diseases, such as inflammation mediated diseases (no data).

IT 784202-90-0P 784204-08-6P 784204-09-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(bradykinin modulator; preparation of bicyclylpropionamides as bradykinin receptor modulators treatment of pain, inflammation, and other conditions)

RN 784202-90-0 CAPLUS

CN Benzenepropanamide, β-[(2-naphthalenylsulfonyl)amino]-N-[1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]-, (βR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 784204-08-6 CAPLUS

CN Benzenepropanamide, 4-fluoro-N-[(2R)-1,2,3,4-tetrahydro-6-[(4-methyl-1-piperazinyl)methyl]-2-naphthalenyl]-β-[[[3-(trifluoromethyl)phenyl]sulfonyl]amino]-, (βR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 784204-09-7 CAPLUS
CN Benzenepropanamide, 4-fluoro-N-[(2R)-1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]-β-[[[3-(trifluoromethyl)phenyl]sulfonyl]amino]-, (βR)- (CA INDEX NAME)

Absolute stereochemistry.



IT 783239-08-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of bicyclylpropionamides as bradykinin receptor modulators treatment of pain, inflammation, and other conditions)
RN 783239-08-7 CAPLUS
CN Carbamic acid, [1,2,3,4-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



OS.CITING REF COUNT:	8	THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)
REFERENCE COUNT:	5	THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> d his

     (FILE 'HOME' ENTERED AT 12:55:17 ON 23 NOV 2009)

     FILE 'REGISTRY' ENTERED AT 12:55:45 ON 23 NOV 2009
L1             STRUCTURE UPLOADED
L2           0 S L1 SSS
L3           2 S L1 FULL

     FILE 'CAPLUS' ENTERED AT 13:02:25 ON 23 NOV 2009
L4           1 S L3 FULL

     FILE 'REGISTRY' ENTERED AT 13:07:23 ON 23 NOV 2009
L5             STRUCTURE UPLOADED
L6           0 S L5 SSS
L7           2 S L5 FULL

     FILE 'CAPLUS' ENTERED AT 13:11:07 ON 23 NOV 2009
L8           1 S L7 FULL

     FILE 'REGISTRY' ENTERED AT 13:12:40 ON 23 NOV 2009
L9             STRUCTURE UPLOADED
L10         14 S L9 SSS
L11       9552 S L9 FULL

     FILE 'CAPLUS' ENTERED AT 13:14:16 ON 23 NOV 2009
L12       1809 S L11 FULL

     FILE 'REGISTRY' ENTERED AT 13:16:48 ON 23 NOV 2009
L13            STRUCTURE UPLOADED
L14          0 S L3 SSS
L15          2 S L13 SSS
L16        291 S L13 FULL

     FILE 'CAPLUS' ENTERED AT 13:18:36 ON 23 NOV 2009
L17         14 S L16 FULL

=> log y
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                     ENTRY    SESSION
FULL ESTIMATED COST                                  79.46     851.10

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)      SINCE FILE      TOTAL
                                                     ENTRY    SESSION
CA SUBSCRIBER PRICE                                 -11.48     -13.12

STN INTERNATIONAL LOGOFF AT 13:19:24 ON 23 NOV 2009
```